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Abstract  
 
A significant number of drugs such as antibiotics, immunosuppressants or antiepileptics exhibit 
narrow therapeutic windows and high inter-individual pharmacokinetic variability. In such 
cases, Therapeutic Drug Monitoring (TDM) is compulsory in order to optimize the efficacy of 
the drug while avoiding adverse effects. Concentration measurements required for dose-
adjustments are however complex and are therefore only performed at specialized facilities. 
The development of a device for accurate whole-blood quantification of critical drugs at the 
Point-of-Care (POC) would enable fast time-to-result and provide a more convenient solution 
to patients. 
This thesis aimed at the design of sample-to-result devices comprising microstructures that 
allowed for the quantification of small molecules in blood. The designs were based on the 
development and use of miniaturized fluorescence polarization immunoassays (FPIA). The 
main feature offered by the FP assay format was the ability to perform homogeneous 
measurements with no separation or washing steps required, making it particularly suitable for 
automation.  
An important result of this thesis is the demonstration that the concentration of small drugs 
can be quantified in whole blood within paper-like membranes using Fluorescence Polarization 
Immunoassay (FPIA). Different types of paper-like materials such as glass microfibers, 
cellulose and filter paper were screened for artefacts such as scattering or autofluorescence. 
Accurate determination of the fluorescence polarization of red-emitting fluorophores at sub-
nanomolar concentrations was found possible within glass fiber membranes. This enabled the 
development of a competitive immunoassay for the quantification of the antibiotic tobramycin 
using only 1 ?L of plasma in glass fiber micro-chambers. Furthermore, the same membrane 
was used for transversal separation of blood cells followed by accurate FPIA read-out at the 
bottom part of the micro-chamber. Within the therapeutic window, coefficients of variation were 
around 20% and recoveries between 80-105%, demonstrating the ability to run quantitatively 
both clinical chemistry and sample preparation by incorporating FPIA in glass fiber 
membranes. 
Another important step towards a POC device was the design of a compact, bench-top FP-
based analyzer. In this case, glass capillaries were used as detection chambers as they cause 
little light scattering and for reasons of convenience. Once assembled, the performance and 
functionality (i.e. ease of alignment of the optical parts, sensitivity) of the analyzer were 
assessed by measuring total fluorescence intensity as well as anisotropy of the prototypical 
fluorescent dye fluorescein. Furthermore, the new optical system was employed for 
tobramycin quantification previously spiked in plasma samples showing good analytical 
performance in terms of coefficients of variation and recoveries within the therapeutic range 
of the drug. 
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A more challenging class of drugs are the immunosuppressants, administered in cases of 
organ transplantation. For tacrolimus, for instance, due to its distribution within red blood cells 
and its very low concentration, an assay can become laborious in terms of sample preparation 
and implementation into microstructures. Here, several fluorescent derivatives of tacrolimus at 
different wavelengths were synthesized. Their affinity for various biorecognition molecules 
were tested allowing the choice of a ligand-receptor pair for the development of a FPIA for 
tacrolimus quantification in buffer. Next, attempts were undertaken to adapt the immunoassay 
for analysis in whole blood samples. Considerable challenges due to the complexity of the 
matrix were revealed and initiated efforts to improve the whole blood preparation techniques 
with the aim of quantifying tacrolimus within its therapeutic range. 
With the aim of paving the way towards personalized therapies, this thesis makes the 
realisation of a POC for TDM a realistic goal. 
 
Keywords: Therapeutic Drug Monitoring; point-of-care; microfluidics, paper, tobramycin, 
tacrolimus, Fluorescence Polarization Immunoassay;  
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Sommario  
Un significante numero di farmaci come gli antibiotici, gli immunosoppressori o gli antiepilettici, 
presentano una stretta finestra terapeutica e gradi variazioni farmacocinetiche inter-individuali. 
In questi casi, il monitoraggio dei farmaci tera???????? ?? ??????????? ???? ?????? ??????????
???????????????????? ??????????????????????? ????????????????????????????????????????????????????
??????????????? ??????????? ???? ?????????????? ?????? ????? ????? ????????? ?????????? ?? ???
conseguenza sono eseguite nelle strutture specializzate. Lo sviluppo di un dispositivo portatile 
?? ?????? ?? ??? ?????????? ???? ??????????? ???????????????? ???? ???????? ???????? ?????????????? ???
risultato veloce e una soluzione più conveniente per gli pazienti. 
????????????della tesi è stato il design di piattaforme analitiche con microstrutture incorporati, 
che hanno permesso la quantificazione di piccole molecole in sangue. Lo sviluppo di queste 
?????????????????????????????????? ??????????????????????????????????????????? ?????? ?????????????
polar??????????????????????????????????????????????????????????????????????????????????????????????
eseguire misure omogenei, facendo questa tecnica particolarmente adatta per 
??????????????????? 
La tesi ha dimostrato che la concentrazione dei farmaci di basso peso molecolare può essere 
quantificata in sangue dentro le membrane di carta utilizzando il metodo di Fluorescenza 
Polarizzata. Diversi tipi di carta e microstrutture simili come per esempio le, cellulosi e carta 
da filtro sono stati analizzati in quanto riguarda la dispersione della luce ma anche 
??????????????????. Questo ha permesso lo sviluppo di un metodo competitivo per la 
?????????????????????????????????????????????????????????????????????????????????????????????????
vetro. Inoltre, le stesse membrane sono state utilizzate per la separazione trasversale del 
sangue competo, seguito da lettura accurata della fluorescenza polarizzata nella parte 
inferiore della micro-camera di misura. Nella finestra terapeutica, i coefficienti di variazioni 
sono stati intorno a 20% e la concentrazione ricoverata tra 80-???????? ??????????????????????
eseguire quantitativamente chimica clinica e preparazione del campione tramite 
?????????????????????????????????????????????????????????????????????????????. 
Un significante passo verso un dispositivo POC è stato il design e sviluppo di un dispositivo 
analitico miniaturizzato e compatto basato sulla fluorescenza polarizzata. In questo caso, i 
capillari di vetro sono stati utilizzati come contenitori di misura per via della loro bassa 
dispersione della luce e motivi di convenienza. Una volta assemblato, la funzionalità, è stata 
valutata ?????????? ???????????? ??? ????????????? ??????? ????? ????? ?????????????? ???????????????
fluorescente prototipo, fluoresceina. Inoltre, il nuovo sistema ottico, utilizzato per la 
quantificazione della tobramicina, in precedenza aggiunta in campioni di plasma, mostra 
buona caratteristica analitica in termini di coefficienti di variazioni entro la finestra terapeutica 
del farmaco. 
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Una classa di farmaci più esigenti sono gli immunosoppressori, somministrati in casi si 
trapianto di organi. Per tacrolimus, a causa della sua distribuzione nelle cellule rosse e la sua 
concentrazione molto bassa, un metodo per la sua quantificazione può diventare laboriosa in 
termini di preparazione del campione e implementazione nelle microstrutture. Qui, diversi 
???????????????????????????????????????????????????????????????????????????????????????????????????
varie molecole biocompatibili è stata testata permettendo la scelta della coppia ligando-
recettore adatta per lo sviluppo di FP per la quantificazione di tacrolimus in buffer. In seguito, 
tentativi sono stato fatti per adattare il test per l??????????????????????????????? 
Con lo scopo di aprire la strada verso le terapie personalizzate, questa tesi prevede che la 
realizzazione di una piattaforma analitica miniaturizzata per il monitoraggio dei farmaci è un 
obiettivo realistico. 
 
Parole chiave: monitoraggio terapeutico dei farmaci; dispositivo point-of-care; sistemi 
microfluidici, carta, tobramicina, tacrolimus, Fluorescenza Polarizzata;  
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Aim and outline of the thesis  
 
Blood tests for monitoring therapeutic drugs are nowadays exclusively performed in central 
laboratories, even when therapies demand for immediate decisions. This requires significant 
amounts of sample while being expensive and introducing significant delays that may affect 
the clinical outcome. Rapid and accurate whole-blood quantification of critical drugs at the 
point-of-care would enable fast turnaround time and provide a convenient solution for patients. 
The central aim of this PhD project, maturated within the NanoTera Program, is to study and 
design immunoassays based on optical detection suitable for the implementation into a fully 
integrated Point-of-Care device for personalized therapeutic drug monitoring for various 
classes of small drugs.  
 
In particular, this thesis presents new results on:  
 ? assay designs with reduced and simplified sample pre-processing by exploring the ability 
of paper and paper-like membranes, such as glass fiber microstructures, to accommodate 
measurements of small drugs with optical techniques;  
 ? incorporation of whole blood quantitative assays for small (therapeutic) molecules into 
paper-based microstructures while preserving the required performance of the overall test; 
 ?  development of an immunoassay format that can be universally extended to various types 
of microstructures such as glass capillaries;  
 ? design and test of a novel optical bench-top system for drug monitoring with improved 
performance of the overall test; 
 ? development of a simplified, novel immunoassay for an immunosuppressant used in organ 
transplantation;  
 
Considering the various facets of the research, the thesis is structured in the following way:  
 
Chapter 1 will introduce the clinical practice of TDM and key parameters like pharmacokinetics 
(PK) and pharmacodynamics (PD) will be defined. Moreover, classes and characteristics of 
drugs requiring TDM will be described as well as the analytical methods implicated in their 
quantification. Furthermore, by looking at gaps and opportunities in the state of the art for POC 
devices, challenges will be highlighted that should be considered in the development of a Point 
of Care test for the quantification of small molecules. The first chapter will conclude by 
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describing the principles of competitive immunoassays, their analytical features and the 
principle of FPIA.   
 
Chapter 2 introduces a novel approach for a quantitative test for in vitro Diagnostics (IVD) 
based on a competitive optical fluorescence polarization immunoassay (FPIA), taking 
advantage of the features of paper and paper-based microstructures. Based on several 
developments to perform blood separation and drug quantification, the feasibility to measure 
small drugs within micro-chambers made of paper-like materials such as glass fiber 
microstructures was demonstrated. The choice of the fluorophore seemed to be an important 
factor in order to allow for measurements in whole blood and further implementation into 
microstructures.  
 
Chapter 3 will describe the analytical performance of a compact FP analytical device designed 
by the group of Prof. Martial Geiser at the HES-SO Valais-Wallis. Here, an important aspect 
consists in the fact that the immunoassay is incorporated within squared glass capillaries in 
replacement of the standard well-plates, and thereby requires a minimal volume of reagents 
and sample (up to 1 µL), allowing for a minimally invasive approach for blood collection. The 
performance achieved with the demonstrator will be described and discussed by comparison 
with a commercial reader. Finally, the results will be presented of the same immunoassay 
carried out using serum separated from whole blood using a passive microfluidic PDMS device 
designed by David Forchelet from the laboratory or Prof. Phillipe Renaud, at EPFL.  
 
Chapter 4 will focus on immunosupressants, a particular class of drugs used in organ 
transplantation. Here, the goal is to design a sensitive FPIA for tacrolimus (TAC) with simplified 
sample preparation and rapid quantification. For this reason, different fluorescent derivatives 
of TAC were synthesized and tested with regards to different biorecognition molecules. 
Moreover, different sample preparation procedures were explored and applied to whole blood 
samples. The current format of the assay requires further optimization for the quantification of 
tacrolimus within the therapeutic range in real samples.  
 
Chapter 5 concludes the thesis with an overview on the achievements of this thesis. Future 
perspectives such as integration of additional sample preparation steps, multiplexing, and 
validation of the demonstrator in clinical settings, will also be discussed.

1. General Introduction 
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Chapter 1:  
 
1. General Introduction 
 The research community nowadays has a great opportunity to develop novel analytical 
techniques, chemicals and materials that will shape the future of diagnostics. A great change 
in clinical practice is driven by the emergence of Point-of-Care (POC) devices, novel diagnostic 
and therapy tools, that will further enable the screening and monitoring of patients and lead to 
personalized and controlled therapy [6]. These novel developments rise a series of questions 
such as:                                                                                                                                               ? Could fast, accurate and minimally invasive Point of Care devices improve the clinical 
outcome of Therapeutic Drug Monitoring and have a positive impact on the overall 
costs?  ? How healthcare would benefit from these novel medical devices? ? What are the most appropriate approaches to develop quantitative assays of small 
molecules in biological samples that could be integrated within devices?                                              
I review here some potential answers to these questions by looking at the specific needs of 
drug monitoring and recent progresses in the development of Point-of-Care testing.  
 
1. 1 Therapeutic Drug Monitoring  
 
1.1.1 Principles of Therapeutic Drug Monitoring 
 
Quantification of drug concentrations in blood can be traced back to 1932, when lithium and 
digoxin were the first therapeutic agents recognized to be worth monitoring in this way [1]. 
Since then, a wide number of different therapeutics have been assessed for monitoring. 
 
Therapeutic Drug Monitoring (TDM) is a multi-disciplinary clinical speciality aimed at improving 
patient care by individually adjusting the dose of drugs for which clinical experience or clinical 
trials have shown it improved outcome in general or specific populations. It can be based on 
a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori 
measurement of blood concentrations of drugs (pharmacokinetic monitoring) and/or 
biomarkers (pharmacodynamic monitoring)1. The type of drug and treatment, the metabolism, 
a narrow therapeutic range as well as variability between patients due to age and/or 
                                               
1
 Definition of the International Association of Therapeutic Drug Monitoring and Clinical 
Toxicology (https://www.iatdmct.org/about-us/about-association/about-definitions-tdm-ct.html) 
 1. 1 Therapeutic Drug Monitoring 
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physiological state (i.e. gender, pregnancy) are just some of the parameters that can strongly 
influence the pharmacokinetic and pharmacodynamics properties of the drug. This is 
illustrated in Figure 1.1, which highlights that TDM is based on the assumption that there is a 
defined relationship between dose and plasma or blood drug concentration. 
 
 
 
Figure 1.1: Schematic representation of the interrelationship between pharmacokinetics and 
pharmacodynamics, (adapted from [3]). 
The course of a drug in the body is defined as pharmacokinetics and it combines a multitude 
of processes like Absorption, Distribution, Metabolism and Excretion (ADME), being described 
as follows:  ? Liberation: the release of a drug from the dosage format (tablet, capsule, extended-
release formulation);  ? Absorption: movement of the drug from the site of administration (e.g. for drugs taken 
orally) to the blood circulation. Many factors affect this stage, including gastric pH and 
presence of food particles, as well as the efflux mechanism if present in the gut. First-
pass metabolism plays an important role in determining the bioavailability of a drug 
given orally; ? Distribution: the movement of a drug from the blood circulation to tissues/target 
organs. Drugs may also be bound to serum proteins, ranging from no protein binding 
to 99% protein binding;  ? Metabolism chemical transformation of a drug to the active and inactive metabolites. 
The liver is responsible for the metabolism of many drugs, although drugs may also be 
metabolized by a non-hepatic path or be subjected to minimal metabolism;  ? Excretion: the elimination of the drug from the body via renal, biliary or pulmonary 
mechanisms [2], [3].  
 
For a significant number of drugs, a given dose does not lead to identical concentration-time 
profiles in all patients[4]. Figure 1.2 shows an example of inter-patient variability when 
1. General Introduction 
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voriconazole, an antifungal medication used to treat several fungal infections, is administered 
to new-borns.  
 
 
 
Figure 1.2: Inter-patient variability of voriconazole: drug concentration in dependence of the 
administered dose of voriconazole; Adapted from [5]. 
High pharmacokinetic variability can make it difficult to predict how a patient will respond to a 
drug. Moreover, with decreased predictability comes increased risks of both toxicity and 
subtherapeutic dosing in the individual patients. To decrease inter-individual pharmacokinetic 
differences, doses should ideally be tailored to the individual patient (individualized dosing)[6]. 
 
As represented in Figure 1.3 and 1.4, in a dosing study it is important to consider peaks 
(highest concentration) and troughs (the lowest concentration) of drug levels following dose 
administration. The aim of administering multiple doses is to maintain the drug concentration 
within the therapeutic window for the entire duration of the therapy. The samples are collected 
at a prescribed time after the dose is administered in order capture the peak concentration 
while another sample must be collected prior to the next dosage to capture the trough level. 
Therefore, precise timing of dose administration, sample collection and concentration 
measurement is o???????????? ????????????????????????????????????????????? 
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In the current context, a point-of-care device would enable drug measurements at the right 
time allowing for a personalized dosage and enabling maximum precision in drug therapies. 
 
1.1.2 TDM flow nowadays 
 
At present, TDM relies on concentration measurements performed in large medical 
laboratories and requires the collection of mL of blood, which might become uncomfortable for 
the patient on a long-term therapy. The samples need to be transferred to the specialized 
laboratory where the measurements are performed. After examination by the laboratory staff, 
the measurement results are sent to the medical doctor who is in charge of the patient. The 
clinical interpretation of the results represents a key challenge as the medical doctor is 
responsible for translating a drug concentration value into an appropriate decision of dose 
adjustment [8]. Figure 1.5 describes the classical procedure from sample collection to clinical 
interpretation and therapeutic decision, process that can sum up to several hours in a non-
emergency setting, having potential detrimental consequences for patients in a critical 
condition.  
 
 
 
Figure 1.5: Therapeutic Drug Monitoring process today 
 
TDM results are strongly dependent on the following factors:  
 ? Time sampling: sample collection should occur at the correct time after drug 
administration (errors in time sampling are probably most responsible for mistakes in 
interpreting results);  
1. General Introduction 
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? Type of sample and pre-treatment: the reagents used in the pre-treatment must be 
compatible and adapted to the properties of the molecules to be quantified; the pre-
treatment can be complex with extraction, centrifugation, etc. ? Method used: the method or assay applied should be reliable, sensitive and specific, 
preferably with a response in less than 24 hours from the sample collection; tubes, 
preservatives, storage and handling conditions can impact the results; ? Clinical interpretation of the results: into consideration should be taken not only the 
concentration of the drug but also other clinical features (pharmacogenetics, age, 
previous analysis); food, concomitant medication, supplements can also have an 
influence on the results; ? Management of the results: drug dosage decisions [8], [9]. 
 
Therefore, the availability of an automated device to measure drug levels near the patient 
would simplify the time-consuming procedure by allowing medical doctors to promptly act 
based on the results.  
 
1.1.3 Classes of drugs requiring TDM and current techniques    
 
 A drug should satisfy certain criteria to be suitable for therapeutic drug monitoring and these 
include: 
 ? a narrow therapeutic range ? significant pharmacokinetic variability ? a reasonable relationship between plasma concentrations and clinical effects ? an established target concentration range ? availability of cost-effective drug assays [7]. 
Several classes of drugs are commonly monitored to ensure a correct blood concentration, 
including antiepileptics, antiarrhythmic, antibiotics, antineoplastics, bronchilators, and 
immunosuppressants. In addition, many modern drugs involved in therapies requiring a long 
term administration, like HIV [10] or cancer [11], [12],  are good candidates for TDM. 
 
In this thesis, two prototypical small therapeutics belonging to two different classes of drugs 
were used: an antibiotic and an immunosuppressant.  
Tobramycin (TOB), (Figure 16 A), a 465 Da aminoglycoside antibiotic, was employed as a 
prototypical drug for the design of immunoassays implemented within paper-based and 
capillary microstructures. Used against gram-negative bacterial infections, in particular caused 
 1. 1 Therapeutic Drug Monitoring 
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by Pseudomonas aeruginosa, its mechanism of action relies on binding to a site on the 
bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, mRNA 
cannot be translated into protein leading to bacterial death. This drug may be prescribed to 
neonates and children so that it requires special attention to control variations of its 
concentration in the body[13], [14]. At concentrations above the therapeutic range (>10 µg/ml), 
it might cause nephrotoxicity and ototoxicity [15]. Although various methods of monitoring and 
dose adjustment have been proposed for Tobramycin, the most common is to measure a 24-
hour trough concentration and to adjust the dose to maintain the trough concentration below 
a value of 2, 1 or 0.5 mg/L while the requirements for peak levels are between 2-12 µg/mL (1 
mg/mL of tobramycin represents 2.14 mM) [16]. Currently Tobramycin is quantified using 
immunoassays (FPIA and EMIT) [17] but also using chromatography methods like HPLC [18]. 
 
Tacrolimus (TAC), (Figure 1.6 B), known as FK506, is a macrolide immunosuppressant that is 
used for primary immunosuppression after organ transplantation [19]. With a molecular weight 
of 804.031 g/mol, 1mg/mL of tacrolimus represents 1.243 mM. Therapeutic drug monitoring in 
case of Tacrolimus is essential in order to avoid toxicity while maintaining its efficacy. As it has 
a large inter and intra-variability (20-80 %), Therapeutic Drug Monitoring should be performed 
frequently, every day until 14 postoperative days, which requires to monitor with confidence 
the administered dose [20], [21]. This task is particularly challenging due to its narrow 
therapeutic range: levels above 20 ng/mL can cause serious side effects like nephrotoxicity 
and neurotoxicity while levels below 5 ng/mL induce a real risk of organ rejection [22]. 
Moreover, Tacrolimus is strongly bound to erythrocytes and therefore whole blood must be 
used for quantification measurements [23]. A table summarizing the drug characteristics, the 
monitoring requirements and the methods employed in the analysis of immunosuppressants 
will be reported in Chapter 4.  
 
                 Figure 1.6: Chemical structure of A) Tobramycin and B) Tacrolimus 
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Selection of the right analytical method for a therapeutic drug requires the consideration of 
several aspects including the chemistry, the metabolism, the required precision in relation with 
the intended clinical use, the sample volume and the throughput as well as testing costs. The 
LC-MS/MS analytical platform is versatile and specific assays for almost any drug can be 
established. While LC-MS/MS holds the potential for greater specificity compared with 
immunoassays, interference issues induced by the blood matrix are a persistent problem. 
Failure to recognize false results caused by interference in an analysis, especially for critical 
drugs, could lead to serious problems for patients [24].  
 
Immunoassays have the advantage of easy performance on multiplexed, automated, high-
speed clinical analyzers, existing in most hospitals laboratories with fairly good precision; 
however, they are not always available, especially for newer drugs. Immunoassay 
developments and improvements like Florescence Polarization Immunoassay (FPIA), 
Microparticle Enzyme-Linked Immunoassay (MEIA), Enzyme Multiplied Immunoassay 
Technique (EMIT), Cloned Enzyme Donor Immunoassay (CEDIA) play a major role in 
Therapeutic Drug Monitoring. 
 
1.2 Point-of-care Testing 
 
Point-of-Care Testing (POCT) is defined as a medical diagnostic tool that supports patient 
diagnosis in ??????????????????????????????????????????????, the field, or in the hospital and is 
typically performed by non-laboratory personnel. The results of the test are timely and allow 
for rapid treatment of the patient. Therefore, empowering clinicians to make decisions at the 
??????-of-?????????????????????????????????????????? ?????????????????????????????????????????????
challenges of health disparities [25]. In limited-resource or non-existent healthcare settings, or 
where it is very hard to physically access relevant facilities, POC approaches can save 
hundreds of thousands of lives every year [26]. 
 
The benefits of POC diagnostic devices include minimal sample volume (a drop of whole blood 
obtained from a finger prick, up to 25 µL), short turnaround time (TAT), minimal manual input, 
portability, low cost, immediate clinical decision-???????? ???? ?????-of-????? ???????? ??? ?????
they can be successfully deployed at the primary care level [27],[65]. Based on immunoassays, 
they are often called one-step assays, referring to the fact that results can be obtained simply 
after the introduction of sample into the device.  
 
 1.2 Point-of-care Testing 
28 
 
The turn-around time (TAT) it is one of the most important benefit of POCT. For several 
therapies, the time of collection is critical for correct dosage interpretation. For instance, in the 
case of some immunosuppressants, where blood samples should be drawn within a 15-min 
time frame at 2 h post-dose, [28], a POC would offer flexibility in terms of timing for sample 
collection and no anticoagulants would need to be used [29], [30], [31].  
 
Another reason for which a POC is preferred are the pre-analytical factors. It has been 
estimated that pre-analytical errors account for more than two-thirds of all laboratory errors, 
while errors in the analytical phase and post-analytical phase account for only one-third , and 
range from mistakes of filling tubes with an incorrect blood to anticoagulant ratio for 
coagulation tests to the use of empty or inadequately filled tubes [32]. Unfortunately, this 
critical area is often neglected in laboratory investigations and overlooked in quality control 
procedures and troubleshooting investigations [33].  
 
The traditional limitations of POCT are related to the technologies used for performing the 
assay. Adequate accuracy and precision are sometimes difficult to achieve on these devices. 
Moreover, the methodologies employed in POCT differ from those employed in the central 
laboratory. Therefore, standardization across POCT sites or comparison of the results with 
those obtained at a reference laboratory are important measures to ensure quality. Moreover, 
proper training is key to make sure the test is used correctly and delivers the greatest benefit. 
The lack of POCT device for TDM practice might be predominantly due to the high challenges 
linked with the implementation of a technology for small-molecule quantification in a compact 
and reliable miniaturized analytical system.   
 
1.2.1 State-of-the art of existing POCT solutions 
 
In the last 20 years or so, the rise of large-capacity automated systems for analytical 
(bio)chemistry has stimulated the emergence of centralized laboratories performing a wide 
spectrum of diagnostic and genetic analyses. In parallel, many of new POC diagnostic tests 
have been introduced each year [34]. The success of glucose meters, used nowadays for 
measuring glycemia in diabetic patients and which are representing over 50 % of the POC 
worldwide, has motivated people to opt for self-testing. The number of assays available on 
POC platforms continues to grow and nowadays tests cover a broad spectrum of categories 
including thyroid, fertility, cardiac, anemia, tumor markers, drugs of abuse, toxicology, 
adrenal/pituitary, reproductive, allergy, infectious disease, transplant, bone metabolism, 
cytokines, and other special proteins[35].  
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To date, besides the glucose meters, the most common POC devices are the Lateral Flow 
Immmunoassays (LFA) test strips, which rely on capillary-force-driven, passive fluidic flow. 
LFA strips move samples and analytes using the wetting properties of capillaries within porous 
substrate materials or integrated wicking pads. Their advantages include simplicity in design, 
compact form, low cost, disposability, absence of moving parts, and no need for external 
power. Their limitations are variations in flow rate due to sample viscosity variations, site 
temperature, changes in the surface properties of the device over time, and poor batch- to-
batch reproducibility of substrate materials such as nitrocellulose [36]. 
 
One of the first Point-of-Care devices using microfluidics and micro-fabricated platforms was 
the iSTAT device developed in 1983, bought by Abbott in 2004 and used for a wide range of 
blood chemistries like ions, chloride, glucose, gases, coagulation and cardiac markers such 
as troponin I. Figure 1.7 illustrates some of the commercially, hand-held POC devices, used 
nowadays mainly for the cardiac marker troponin, among other targets. 
 
 
Figure 1.7: Examples of Point-Of-Care platforms: 
A. i-STAT is a cartridge-based analyser with all the analytical reagents for the test 
contained within an individual cartridge. The test sample and reagents never enter the 
??????????? ?????? ??ansforms electrical signals from the test cartridge into readable 
results [37].  
B. Cobas h 232 point of care launched in 2007 by Roche Diagnostics, allowing the 
multiplex quantitative determination of Troponin T, creatinine kinase MB, myoglobin, 
NT-proBNP and D-dimer. 
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C. Handheld Minicare I-20 from Philips launched in May 2016; troponin I quantification at 
sub-picomole/L concentrations in few minutes. The immunoassay is based on actuated 
magnetic nanoparticles; the quantification is performed optically through frustrated total  
internal reflection (f-TIR); The device performs whole blood separation on a single-use 
disposable cartridge;  
D. Digital microfluidic cartridge based on a magnetic beads immunoassay performing 
multiplexed tests for quantitative troponin. 
 
Another field where POC devices are of high interest is illicit substance screening. Examples 
of commercial POCT for drugs of abuse (DOA) with molecular weight lower than 1000 Da 
(small molecules) are highlighted in Table 1. However, these devices are mainly qualitative 
and/or semi-quantitative. 
Table 1: Commercially available Point-of-Care devices for small-molecule quantification  
 
 
 
1.2.2 Towards point-of-care devices for small-drug quantification  
 
The growing need for quantitative POC devices for small therapeutic drugs has been 
emphasized in the literature [48]. Nowadays, in the research community, efforts are being 
made to design novel strategies for small-drug quantification (Table 2). These efforts are either 
Type of 
POC 
POCT device Manufacturer Application Product features References 
Unit-use 
(hand-held) 
Point-of-Care Diagnostic 
System 
GenPrime Multiplex- 
DOA 
*High-resolution 
flatbed scanner 
*Lateral flow tests 
*Colour charged 
Coupled Device 
[38] 
 Xprecia Stride Coagulation 
Analyzer 
Siemens 
Healthineers 
Coagulation 
Monitoring 
(Warfarin) 
*Tests PT/INR with lab 
accuracy 
*Fresh capillary whole 
blood  
[39] 
Bench-top 
(sensor-
based) 
Evidence, Evidence Evolution 
and Evidence Investigator 
Randox 
Laboratories 
Multiplex- 
DOA 
*Up to 2000 tests/h  
- 2640 tests/h  
- 702 tests/75min 
[40][41][42] 
 RX daytona, daytona+, 
monaco, Benchtop Clinical 
Chemistry Analyzer 
Randox 
Laboratories 
Multiplex- 
DOA 
*180 photometric 
tests/h 
- 270 photometric 
tests/h 
- 170 photometric 
tests/h 
 
[43][44][45] 
 RX monza Semi-Automated 
Clinical Chemistry Analyzer 
Randox 
Laboratories 
Multiplex- 
DOA 
*128 programmable 
tests  
*192 programmable 
channels 
 
[46] 
 AltairTM 240 Automated 
Chemical Analyzer 
EKF 
Diagnostics 
Chemical 
Analyzer 
*Dual reagent probes 
*240 tests/h 
[47] 
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focused on designing novel bio recognition molecules for the therapeutic drugs, or on exploring 
alternative materials for immunoassay implementation. Research in miniaturization is mainly 
focused on limited reagent consumption, decreased analysis times, increased (separation) 
efficiency and on enabling automation. 
 
Table 2: Efforts in designing new technologies for small-drug quantification to be implemented 
into miniaturized analytical devices. 
 
 
Group  Drugs 
targeted  
Methods 
description  
Analytical 
performance  
Sample 
used  
Features  Ref 
Griss. et. al.  
Nature  
2014 
Methotrexate  
Tacrolimus  
Sirolimus  
CsA  
Topiramate  
Bioluminescent  
Resonance  
Energy  
Transfer   
(BRET) 
100 nM - 1.5 
nM 
C50=500 ± 90 
nM 
Diluted 
human 
serum  
Lucid biosensors: 
* A receptor protein  
*A luciferase  
*A synthetic molecule 
containing a fluorophore 
and a ligand for the 
receptor protein; 
[49] 
Ferguson et al.  
Sci. Transl. Med 
2013 
Doxorubicin  
Kanamycin 
Electrochemical 
detection  
0.1-10 µM 
0.13-2.5 µM 
*Live rats  
*Whole blood 
MEDIC: an 
electrochemical 
aptamer-based sensor 
[50] 
Zhao et al. 
Biosensors and 
Bioelectronics  
2014 
Methotrexate Surface 
Plasmon 
Resonance 
(SPR)  
28?500 nM Human 
serum  
Folic-acid-Au NP 
competition with the 
bioreceptor, immobilized 
on the SPR sensor chip;  
[51] 
Cappi et. al.  Tobramycin  Surface 
Plasmon 
Resonance 
(SPR) 
10-80 µM Human 
serum 
Portable T-LSPR with 
aptamer-functionalized 
Nano-islands 
[52] 
Fornassaro et al.  
Faraday 
discussion 
2016 
Methotrexate Surface 
Enhanced 
Raman 
Spectroscopy 
(SERS) 
0.1-20 mM Human 
serum  
Au nanoparticles 
deposited on paper 
[53] 
Murakami et.al  
Analytical 
Biochemistry  
2004 
Tacrolimus  Enzymatic 
immunoassays 
using micro-flow 
antibody chip  
LOD = 1 ng/mL Whole blood  
Extraction 
with 
ethylacetate: 
hexane 1:1 
Polystyrene beads 
coated with mouse anti-
FK506 antibody 
[54] 
Berrettoni  
2014 
Tacrolimus Internal 
reflection 
fluorescence 
(TIRF) 
0-10 ng/mL buffer An optical biochip [55] 
Tachi  
Lab on a chip 
2009 
Theophylline  Fluorescence 
Polarization  
Immunoassay  
(FPIA)  
0-40 µg/mL Buffer  Pyrex glass substrates 
using standard 
photolithographic and 
wet chemical etching 
techniques 
[56] 
Menotta et al. 
Chimica Acta  
2015 
Tacrolimus  
 
Atomic Force 
Microscopy 
(AFM) 
0-30 ng/mL Whole blood  
followed by 
extraction  
AFM based- biosensor  [57] 
Chang et al. 
Biosensors and 
Bioelectronics 
2014 
 
Cyclosporine 
A 
 
LSAW  
(Leaky Surface 
Acoustic Wave) 
 
LOD: 0.89 
ng/ml 
LOQ: 2.96 
ng/ml 
1-1000 ng/ml 
 
Whole blood 
followed by 
extraction   
 
 
LSAW immunosensor 
immobilized with protein 
A from Staphylococcus 
aureus and monoclonal 
anti-CsA antibody on the 
gold electrode surface of 
piezoelectric crystals, 
which then captured the 
CsA 
[58] 
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For instance, the group of K. Johnsson et al. developed a novel type of molecular biosensor  
able to quantify different molecules in serum, using Bioluminescence Resonance Energy 
Transfer (BRET) as a quantification method [49]. As quantification targets, they focussed 
especially on immunosuppressants (sirolimus, tacrolimus, CsA) but also on anticancer agents 
such as methotrexate enabling this way the possibility of multiplexing strategies.  
 
A very ambitious approach in this sense is in vivo monitoring of small therapeutic molecules 
for TDM proposed by Ferguson et al. using the MEDIC device. [50], [59]. They use aptamers 
as detection molecules. Aptamers are DNA or RNA molecules selected using a procedure 
called SELEX and which are specific for different types of antigens. The advantage of 
aptamers is that they can be screened via in vitro processes against a synthetic library. 
Therefore, even for small inorganic ions or intact cells, specific DNA sequences can be found. 
No cell lines or animals have to be used in the production process. As soon as the aptamer is 
selected, a subsequent amplification by polymerase chain reaction (PCR) can produce a large 
amount with good purity [60]. Another promising approach using aptamers for quantification 
of drugs for TDM in human plasma with a hand-held SPR-based device is described by Cappi 
et al. [52].  
 
Other approaches include miniaturization of already existing assays like for example Tachi et 
al. with FPIA within PDMS micro-channels [61]. Berretoni et al. [55] designed a novel TDM 
POCT biochip for the detection and quantification of calcineurin inhibitors cyclosporin A and 
tacrolimus and the inhibitors of the mammalian mTOR proteins, rapamycin (sirolimus) and 
everolimus, as well as mycophenolic acid. Peculiarly, only data for tacrolimus were obtained 
and although the concept proved to be quite promising, no further work was conducted.  
 
1.2.3 Requirements and benefits of a POC for TDM 
 
Despite the clinical importance of TDM with a wide range of different molecules requiring 
analysis and with time-dependent dosage decisions, clinical diagnostics continues to rely 
entirely on central laboratories as unique testing facilities. In an ideal situation, drug monitoring 
would be performed on site (or near-the patient). However, despite of all the recent efforts and 
advances, this is still far, predominantly due to the high challenge that represent the 
implementation of a technology for small-molecule quantification in a compact and reliable 
miniaturized analytical system.  
 
A POC-TDM device should meet the performance requirements in terms of accuracy, 
??????????? ?? ??? ??? ??????????????? ????????????????? ?????????????? ???? ??????????????????????? ??
POCT must focus on providing appropriate health outcome and cost - effective data while the 
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tests must be reliable and easy to use. Integration, portability, low power consumption, 
automation are just several of the most important requirements that a Point of Care device 
should meet [62]. 
By comparison with the flow of TDM today, Figure 1.8 envisions the future of TDM using an 
on-site sample-to answer device. 
 
Figure 1.8: Schematic scenario of Therapeutic Drug Monitoring using a point-of-care analyser. 
In the scenario of TDM performed using a POC analyser, immediately after the physician takes 
the decision of measuring the drug concentration, the nurse promptly collects a fingerpick drop 
of blood and add it on a microchip implemented with specific sample preparation. Ideally, the 
device should have sensitivity within the pM range for drugs available at low concentrations 
but should also present high specificity for the different metabolites.  
A device that allows for point-of-care testing (POCT) for TDM in real-time will help medical 
doctors avoiding toxic side effects and enhancing drug efficacy. The availability of such 
devices would allow:  
 ? to perform the analysis within minutes in order to supply rapid results to physicians;  ? to complete analytical tests without involving traditional central laboratories, thus 
improving the effectiveness of the process with a corresponding decrease of costs 
(benefiting the Health Care System) [36];  ? to improve the effectiveness of some particular drugs, such as anticancer agents, while 
reducing their toxicity by adjusting the administered therapy in real-time based on the 
real plasma concentration, thus leading to an improved outcome for the patients [63]. 
 
Therefore, reducing cost, time, sample volumes, while maintaining the efficiency, are key 
milestones of a Point of Care design. In general, in a classical laboratory assay for drug 
quantification, addition of an anticoagulant such as EDTA is required to preserve the integrity 
of the sample. With a POC device, steps such as sample collection in tubes or storage and 
transportation would be avoided as the analysis would be performed on site.  
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The cost saving advantages of POCT are a key benefit to help promote drug monitoring so 
that it can reach an important position in the medical device market [37]. There are  
expectations that accelerating patient diagnosis and treatment could improve outcomes, which 
could result in substantial savings [64], [65], [66]. However, even if many studies have tried to 
assess the costs of POC devices versus central laboratories for different applications, there is 
no standardized manner to calculate costs for POCT and their estimation uses traditional 
approaches (fixed vs variable; direct and indirect) [67], [65]. Most of the analyses do not take 
into account, for instance, the financial impact of the reduced volume of blood required for 
POCT versus central laboratory testing [68]. The perspectives on cost of POCT may vary 
depending on whether you are a patient, insurance company, employee, laboratory employee, 
or hospital employee. The billed amount the patient or insurance company sees for POCT will 
usually be less than for central laboratory testing. Billing for POCT is less complete, and 
payment rates for a glucose meter test are less than for a central laboratory test. Therefore, 
the savings for patients and payers for health care are probably many millions of dollars 
annually, while this represents a decrease in revenue for the providers [68]. By choosing the 
proper sample type and reducing the size, the costs and the blood volume loss can be reduced 
as was shown in a study on new-borns with the introduction of a multiplexed POC-blood 
analysis [69]. Finally, yet importantly, the benefit of a POC device for small molecules would 
bring comfort to the patient. In some situations, such as organ transplantation, the drugs are 
administered for life-time and the patient needs to be periodically monitored. This includes 
traveling to the clinical laboratory and invasive sample collection.  
 
Expanding TDM to broader populations of patients by making it available via a POC device 
would improve the outcome of drug therapies with less adverse effects and play a very 
important role in improving treatment efficacy, increasing survival and quality of life. Despite 
all these obvious advantages, currently, there is no robust, sample-to-result device on the 
market enabling quantification of small molecules for therapeutic drug monitoring. This is 
predominantly due to challenges in the implementation of an appropriate technology in a 
compact and reliable miniaturized analytical system. These challenges will be described in the 
following sub-chapter.  
 
1.2.4 Challenges and opportunities 
 
As shown in previous paragraphs, drug monitoring in combination with a POC device can have 
significant benefits. However, for the design of such a device, several challenging aspects 
have to be taken into account.  
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One of the most important requirements is to maintain the analytical performance after the 
integration into the microstructures. The Federal Drug Administration (FDA) advises that the 
imprecision determined at each concentration level should not exceed a coefficient of variation 
(CV) of 20% except at the Lower Limit Of Quantification (LLOQ), where it should not exceed 
25% CV [70]. However, this might be a difficult challenge for the drugs which are administered 
at very low concentrations. For instance, in the case of tacrolimus, which is in the low nM range 
in the blood after administration, dilutions with reagents required for the assay decrease the 
analytical concentration down to the pM range. Hence, maintaining the required analytical 
performance within a miniaturized system in such case can become extremely challenging.  
 
The ability of an assay to be specific towards the target of interest is highly desired. Some 
drugs have metabolites presenting similar potencies as the parent drug and their quantification 
is required for a correct dosage decision. For instance, significant cross-reactivity between 
tacrolimus and its metabolites  has been reported for several immunoassays [71]. Therefore a 
POC device with a high degree of specificity would be highly desirable.   
 
An interesting attribute of a POC - TDM would be a multiplexing capability meaning the 
capability to measure two or more analytes. Multiplexing is often preferred as it can decrease 
the cost per test. While in a clinical laboratory, the operator runs on the same platform 
protocols for different analytes using specific reagents and thus specific assays, this might be 
challenging to implement in a miniaturized device with drugs that exhibit various chemical and 
biochemical properties [72], [73]. 
 
Quality control and standardization among various testing locations and the central laboratory 
are ongoing issues and subject of debates for the applicability of POC devices [74]. These 
open issues include also the data management and the possibility to connect all the POCT 
from different testing locations to each other and to a central medical institution.  
 
1.3 Immunoassays   
 
1.3.1 Principles and classification  
 
???? ????? ?? ??????????? ??? ??????????? ??? ?????? ??? ???? ??? ?? ??????? ??? ???????? ????? ?????
advantage of the antigen ? antibody reaction for detecting an analyte (for example, a hormone, 
a protein, or a drug) [75].  
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This reaction requires from a few seconds to many hours to achieve equilibrium, depending 
on a range of different factors.  The pH, ionic strength, and temperature all affect the reaction 
time. The nature of the reaction can vary considerably and is of profound significance to the 
development of an effective assay. Early immunoassays often had overnight incubations to 
allow the reaction to fully reach equilibrium. However most current immunoassays involve 
comparatively short incubations and do not allow the reaction to reach a state of equilibrium. 
In these assay designs, it is even more important to understand a few simple concepts and 
consequences of the kinetics of the antibody?analyte reaction.  
The theory of immunoassays is excellently described in the Immunoassay Handbook [76] and 
I summarize here the most important aspects citing some excerpts from this reference. 
 
Immunoassay success depends on three important properties of the key reagents in their 
design, the antibodies: ? Their ability to bind to an extremely wide range of natural and man-made chemicals, 
biomolecules, cells, and viruses. This is because antibodies are proteins, and the 
binding sites are derived from a huge number of potential combinations of amino acid 
sequences. Each of the 20 amino acids has its own unique properties for binding and 
orientation, and chains of amino acids can twist and fold to provide binding at multiple 
sites. ? Exceptional specificity for the substance to which each antibody binds. The remarkable 
specificity of antibodies enables minute concentrations of analyte to be assayed in the 
presence of many closely related substances. ? The affinity between an antibody and its target by creating strong non-covalent bond 
that can survive the processing and signal generation stages.  
 
The strength of the antigen-antibody reaction is referred to as the binding affinity. Binding 
affinity is the probability of association of a ligand (antigen) with a binding molecule (antibody). 
The reaction between antibody and antigen may be simplistically described by the Law of 
Mass Action:  
                                                     [Ag] + [Ab]  ??????- Ab]                                   (Equation 1) 
                                                                                                
 [Ag] represents the antigen concentration, 
 [Ab] represent the antibody concentration, 
 [Ag-Ab] is the antigen-antibody complex 
The equilibrium constant Keq, also known as the affinity constant, can be described: 
                                                     Keq = Ka/Kd = [Ag-Ab] / [Ag][Ab]                           (Equation 2)  
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Ka is defined as the association rate constant,  
Kd is the dissociation rate constant [76]. 
   
High affinity depends positively on the rate of association of the two molecules and negatively 
on the rate of dissociation of the complex formed.  
The antibodies can be either polyclonal or monoclonal. However, for immunoassay 
development for drug analysis, monoclonal antibodies are more advantageous than polyclonal 
and this is attributed due to the higher degree of affinity and specificity towards the analyte. 
 
Based on the labeling specifications, immunoassays can be subdivided in: ? Label-free: the assay does not need any label for quantification;  ? On-labelled: meaning the use of a label, such as a fluorescent label, for the detection.  
 
The immunoassays can be further classified in two main groups:  ? Heterogeneous: involves a physical separation of bound and free moieties[77] as for 
example the Enzyme Linked Immunosorbent Immunoassay (ELISA). ? Homogeneous: requires only mixing of a sample and immunochemical reagents 
followed by detection [72]. 
Immunoassays have four main inter-related characteristics whose performance needs to be 
assessed: 
? Sensitivity: ability to quantitatively measure minute concentrations of the analyte; the 
sensitivity of competitive assays is governed by three factors:  
- the equilibrium constant; 
- the error of signal measurement; 
- the level of non-specific binding, where this forms a significant proportion of the 
total binding [76]. ? Specificity: ability to discriminate between closely-related molecular structures. No 
need for prior purification. Specificity is needed to be demonstrated since the analyte 
of interest is critical because most immunoassays are not preceded by extraction of 
the analyte from the matrix of interest[78] ? Accuracy: ability to provide meaningful quantification (through the use of standards); ? Precision: according to International Federation of Clinical Chemistry (IFCC) is 
minimal variation between measurements so that single or duplicate results can be 
trusted. Within-run precision is defined as the precision of the same sample run on 
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several occasions within the same assay while between run is the ability to reproduce 
the same result from run to run and from day to day [79].  
 
1.3.2 Analytical aspects regarding competitive immunoassays  
 
Competitive design uses only one antibody and is mostly applied for analytes with small 
molecular weight. These class of immunoassays are preferred for small-molecule 
quantification mainly due to the technical difficulty involved in creati??????????????????????????
with relatively small analytes. Predetermined amounts of labelled drug and antibody are added 
to the specimen followed by incubation. In the basic design, the analyte molecules present in 
the specimen compete with labelled molecules for the antibody binding sites molecules. If the 
signal is generated when the labelled xenobiotic binds to an antibody molecule, the signal is 
inversely proportional to analyte concentration in the specimen (e.g., fluorescence polarization 
immunoassay [FPIA]). On the other hand, if the signal is generated by an unbound labelled 
xenobiotic, the assay signal is directly proportional to the xenobiotic concentration (e.g., 
enzyme multiplied immunoassay technique [EMIT]).  
The advantage of homogeneous assays is that after incubation, a separation step is not 
required to distinguish the signal produced by antibody-bound and free label. Nevertheless, 
extraction of the analytes with solvents may be useful before to the immunoassay to increase 
selectivity[80].  
 
Among the most commonly employed homogeneous immunoassays are: 
? Fluorescence Polarization Immunoassay (FPIA): the method uses a fluorescent-
labelled drug and an antibody specific for the drug. When the drug from the patient 
sample is present, it will compete with the fluorescent derivative for the binding sites of 
the antibody. Polarized light is then emitted in certain directions depending on whether 
the fluorescent derivative is bound to the antibody or not. The greater amount of the 
drug in the sample, more fluorescent labeled drug will rotate free in solution generating 
a signal inversely related to the concentration of the drug.  ? Enzyme Multiplied Immunoassays Technique (EMIT) is an enzymatic technique 
based on the competition for the target analyte antibody binding sites. Free analyte 
analog molecules labeled with an enzyme, for instance glucose-6-phosphate 
dehydrogenase enzyme, are added to the test solutions to compete to the analyte to 
be tested. The active enzyme reduces NAD (no signal) to NADH (absorbs at 340 nm), 
?????????????????????? ???????????????????? ?????????????????????????????????????????
enzyme becomes inactive, and so the signal is generated by the free label, and signal 
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intensity is directly proportional to the analyte concentration [48]. It is used mainly for 
quantification of therapeutic drugs such as immunosuppressants or antibiotics but also 
for quantification of recreational drugs and different proteins. ? Cloned Enzyme Donor Immunoassay (CEDIA): an enzyme is genetically engineered 
into two inactive fragments: a small one called enzyme donor (ED) conjugated with the 
drug analogue, and a larger fragment enzyme acceptor (EA). When the two fragments 
associate, the full enzyme converts a substrate into a cleaved coloured product. If drug 
analyte molecules are present, they will compete with the ED-labelled drug in solution 
for the limited antibody sites, so that free ED-labelled drug analogue will bind to EA 
generating a colorimetric signal directly proportional to the amount of analyte. 
analysis[81].  ? Particle enhanced turbidimetric inhibition immunoassay (PETINIA): the principle 
relies on the fact that, in the absence of analyte, free antibodies bind to drug 
microparticles conjugates to form aggregates that absorb in the visible range. When 
the analyte is added, the antibody binds to the free analyte preventing the aggregation 
of microparticles. Therefore a reduction in absorbance (or turbidimetry) is observed 
and the signal is inversely proportional to analyte concentration [48]. 
In the following paragraph theoretical aspects of FPIA principle as well as advantages will be 
described.  
1.3.3 Fluorescence Polarization Immunoassay principle  
 
Fluorescence polarization/fluorescence anisotropy (FP/FA) is a versatile solution-based 
technique that has been widely used to study molecular interactions, enzymatic activity, and 
nucleic acid hybridization. After its first theoretical description in 1926 by Perrin, the application 
has evolved from obtaining binding isotherms under carefully controlled settings to the study 
of small molecule-protein, antigen-antibody, and hormone-receptor binding in miniaturized 
automated settings. It was not until the mid-1990s that FP was adopted in high throughput 
screening to facilitate the drug discovery process, with its use being extended from direct 
interaction studies to complex enzymatic assays [82]. 
 
In particular, Fluorescence Polarization Immunoassay (FPIA) is widely used in central clinical 
laboratories for therapeutic monitoring of small molecules and drug of abuse testing [72]. The 
principle of FP derives from the fact that the degree of polarization of a fluorophore is inversely 
related to its molecular rotation (Figure 1.9), itself being largely driven by Brownian motion. 
Quantitatively, FP/FA is defined as the difference of the emission light intensity parallel (I||) 
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and perpendicular (I?) to the excitation light plane normalized by the total fluorescence 
emission intensity [83] [82].  
 
Polarized light describes light waves that are only present in a single plane of space. After 
absorption of polarized light, small fluorescent molecules in solution rotate rapidly before the 
light is emitted as fluorescence. The emitted light will be released in a different plane of space 
from that in which it was absorbed and is therefore called unpolarized light. 
 
 
Figure 1.9: Fluorescence Polarization Immunoassay principle: fluorescein-labelled drug 
competes with unlabelled drug for antibody sites. The small, free drug-fluorescein rotates 
faster leading to less polarized emission. Larger antibody-drug-fluorescein complexes rotate 
slower and produce more polarized emission.  
 
Fluorescence anisotropy is usually determined by the measurements of fluorescence emission 
in parallel and perpendicular planes. The degree of polarization (P) or anisotropy (r) is 
calculated according to the following equations [84]:  
 ?????????????????????????? ? ??? ? ??????? ? ?????? and     ? ? ? ??? ? ??????? ? ?????          (Equation 3, 4)          
                                                         
where I? is the fluorescence emission measured in the plane parallel to the plane of excitation 
and I? is the fluorescence emission measured in the plane perpendicular to the plane of 
excitation.  
The polarization (P) and anisotropy (r) values can be integrated as follows [85]: 
 
                                      ? ? ????? ? ??? and ? ? ????? ? ???                      (Equation 5, 6) 
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FA and FP, both depend on the intensity ratio, involving the same type of measurement. The 
dependence of the FP/FA on the molecular motility can be described using Per??????????? 
[86]: 
  ??????????????????????????????????????????? ? ???? ? ? ?????? ? ??????? ? ?????                           (Equation 7),  
where P0 is the fundamental polarization of the dye, ? is the excited-state lifetime of the dye 
??????????????????????????correlation time of the fluorophore. For a hydrodynamic sphere, these 
equations can be translated as:  
 
                                                            ? ? ? ????                                           (Equation 8), 
??????????????????????????????????????????? ???????????????????????????????ent dye, R is the gas 
constant and T is the absolute temperature.  
Equation 8 completes the connection between molecular size and FP/FA, leading to the 
following conclusions:  ? FP increases with molecular size of the dye ? FP increases with the viscosity  ? FP decreases with the life-time of the dye 
 
The difference in the way polarization and anisotropy is defined is the presence of a second 
perpendicular intensity term in the denominator. The anisotropy of a mixture (free tracer and 
tracer bound to antibody) is the weighted average of the anisotropies of the individual 
components, i.e. the anisotropy varies linearly with the amount of free tracer (in percentage) 
and for this reason fluorescence anisotropy is more used in biochemical and biophysical 
research. 
 
It is important to note that the fluorescent probes must be designed to give maximum 
polarization/anisotropy change upon binding to the target receptor. For this reason the linker 
between the fluorophore and the pharmacophore must be as short and rigid as possible [87].  
 
Furthermore, when designing competitive immunoassays, limiting concentrations of antibody 
and tracer are required to reach the necessary analytical sensitivity. In particular, tracer 
concentrations dictate the range of concentrations in which an effective competition occurs 
with the analyte and therefore the ultimate assay sensitivity. Therefore, the lowest possible 
tracer concentration that allows for reliable detection of label and does not affect competition 
is desirable for highest sensitivity [88].  
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FPIA results in an inverse dose-response curve (Figure 1.10) so that low levels of analyte 
result in a high anisotropy while high concentrations correspond to low anisotropies.  
 
Figure 1.10: Typical FPIA dose-response curve describing the relationship between assay 
signal and analyte concentration, where IC50 is the concentration required to produce 50% 
inhibition, in this case, corresponding to 50% displacement of tracer from antibody binding. 
The fit is performed using a 4-parameter equation (Hill equation) and the slope is described 
by the rate. For ligand-binding studies, with no cooperativity in the direct binding mode, the 
rate is 1 while for competitive assays, the rate is different than 1 and depends, among others, 
on the concentration of the tracer. 
FPIA is suitable for small molecules, but not large ones, for two main reasons: 
 ? First, binding of a large antigen to an antibody that may be of similar mass produces a 
smaller relative change in the tumbling rate and thus a smaller change in polarization; 
 ? Secondly, most fluorescent labels have excited state lifetimes in the range of 10?9?
10?7 s, which is too short to permit rotational reorientation of larger biopolymers [72].  
It is important to note that IgG antibodies have a calculated rotation between 10?7 and 
1.2 x 10-7 s, with the assumption that the molecule is rigid. However, several 
experiments showed that the observed polarization is determined by Brownian rotation, 
not of the whole IgG molecule but of his parts, which is substantially smaller (under 
10?7 s), being interconnected by flexible bonds [89]. 
 
The utility of FP/FA in the clinical and biomedical sciences is large providing accurate and 
sensitive measurements for a variety of drugs like toxicology analytes, drugs of abuse and 
some hormones [90], [91].   
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While FP assays are relatively simple to perform with good precision and sensitivity, they 
require specialized instrumentation that is not routinely available or commonly used. In 
addition, the FPIA tests marketed by market leaders in clinical analyzers such as Roche 
Diagnostics with the Cobas series (Figure 1.11 A) or by Abbott Laboratories with the TDx or 
AxSYM analyzer (Figure 1.11 B) can only be run on their specific analyzers, further restricting 
the application of this platform, particularly in automated clinical laboratories[24].  
 
Figure 1.11: Examples of clinical analyzers used nowadays in clinical settings: A) Cobas 
Integra from Roche Diagnostics B) AxSYM from Abbott Laboratories. 
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Chapter 2  
2. Incorporation of Fluorescence Polarization Immunoassays into paper 
microstructures 
 
In this present chapter, I demonstrate the feasibility of directly determining the concentration 
of small therapeutics in whole blood within paper-like membranes using Fluorescence 
Polarization Immunoassay (FPIA).  
 
2.1 Paper-like substrates for sample preparation and quantification of drug 
concentration 
 
The first paper-based sensor can be considered the invention of paper chromatography by 
Martin and Synge, who were awarded with the Nobel Prize in chemistry in 19522. Another 
achievement in the field was the commercialization of the pregnancy test, which can be 
considered as one of the most used point-of-care biosensors. After the pregnancy test, other 
diagnostic point-of-care paper-based devices for diabetes and for the detection of biomarkers. 
More recently the development in this field has been extended towards the microfluidic paper 
analytical devices (µPADs) [92]. 
 
Paper and paper-like microstructures are excellent supports for diagnostics due to several key 
properties such as: biocompatibility, three-dimensional fibrous structure[93], high surface area 
[94] and facilitated storage of dried reagents [95]. Paper is also used as a support for 
qualitative tests for analytes with applications covering clinical diagnostics, organic and 
inorganic chemical analysis, environmental and geochemical analysis, and pharmaceutical 
and food chemistry. Lateral-flow immunoassays are a highly engineered and broadly used as 
paper-?????? ??????????? ???????? ????? ???? ???????? ????????? ?????????? ??? ?? ????? range of 
analytes using labelled antibodies. Paper also is used in other areas such as: chemistry for 
synthesis of peptides and small molecules, as a platform for microarrays and lately, from drug 
of abuse quantification in the lateral flow assay format[96] to direct synthesis of DNA in paper 
[97]. [98].  
 
Recently, Cate and al. [99] published a comprehensive review regarding the efforts in 
designing paper-based devices focusing on the fabrication, the incorporation of 
functionalities, the detection and read-out approaches within ??????. Figure 2.1 illustrates 
                                               
2
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some of the applications and designs of the paper and paper-based platforms in current 
research.   
 
 
Figure 2.1: Examples of two-dimensional paper-based devices: A) Wax stamping with 
movable type printing; B) Wax dipping. C) Screen-printed wax device and electrodes. D) Wax 
drawing through a stencil. (E) Wax printing. (F) Inkjet etching of polystyrene in paper with 
toluene (G) Inkjet printing of AKD (H) Flexographic printing of polystyrene (I) Photoresist 
patterning with screen-printed electrodes. (J) Computer controlled knife cutting in 
nitrocellulose. (K) Laser-cut hollow channels. (L) Vapor-phase polymer deposition. (M) 
Chemical modification with alkylsilane self-assembling and UV/O3 patterning. Adapted from 
[99]. 
 
The trend towards functionalization ??? ??????? ??????? ???? the integration of multistep 
processing, preferably automated and extends to chemical surface modification or printing 
conductive materials for paper-based electrodes. For the detection of the analytes, the most 
common methods employed are: electrochemical, chemiluminescence or the colorimetric-
based detection. In order to achieve quantitative analysis in paper-based diagnostics, cameras 
or scanners are used to record the colour intensity due to its relationship with the amount of 
analyte and Figure 2.2 shows examples of such devices.  
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Glass fibers are well known as blood separator keeping the RBC on the surface but due to the 
challenge raised by the relatively rough surface characteristics [95] it has never been coupled 
with direct quantitative measurement in paper. For this reason, glass fiber membranes may 
be a good candidate as a matrix for paper-based microfluidics, as it is a material which consists 
of numerous extremely fine fibres of glass, with a fine capillary structure and is biochemically/ 
chemically inert. Even though paper is extensively used in diagnostic tests, the direct 
quantification of small molecules combined with sample preparation is still limited. 
 
Herein, we demonstrate the applicability of FPIA within fiber-glass membranes for drug 
quantification in human samples using as model the small molecule antibiotic, tobramycin.  
 
The assay was optimized for tobramycin quantification using whole blood. The design was 
characterized with respect to the fluorescence background between different types of paper 
chosen and the possibility to measure polarization within them. Firstly, we synthesized a novel 
tracer whose fluorescence is not impacted by the biological samples and we compared it with 
a green fluorescent dye. Due to the low fluorescent background and ability to host FP, fibres-
glass membranes were fitted for our application and further chosen for Tobramycin 
quantification.  
 
The proof-of-concept for drug quantification within fiber-glass membranes consists in a single-
step procedure: a sample processing system (i.e. separation of red blood cells) with 
simultaneous small molecule quantification measurements through a competitive 
Fluorescence Polarization Immunoassay.  
 
2.3 Materials and methods 
 
2.3.1 Chemical Reagents 
Tobramycin (99 % purity), kanamycin sulfate, dimethylformamide, phosphate buffered saline 
(PBS) were purchased from Sigma Aldrich (St-Louis, USA), Atto 655 ? NHS ester from ATTO-
TEC (Siegen, Germany) and paraffin from Droguerie de la Majorie (Sion, Switzerland). 
Fluorescently-labelled tobramycin and antibodies specific for tobramycin were from a 
commercial kit for FPIA on Roche Cobas Integra 400 (Roche Diagnostics GmbH, Basel, 
Switzerland).  
 
Blood samples:   
All blood samples were purchased from the Interregional Transfusion Centre (Bern, 
Switzerland). They were collected from healthy volunteers in K3EDTA tubes, shipped and 
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stored at 4°C and used within a week from collection date in order to avoid the lysis of red-
blood-cells. Plasma was obtained by centrifuging blood samples at 2000 rpm for 20 minutes 
at 4°C, was stored at -20°C and used within a month.  
 
Spiked samples:  
For the FP quantitative analysis in plasma or whole blood, a 2 mg/mL stock solution of 
tobramycin was prepared in Milli-Q water. From this stock solution, diluted solutions of 
tobramycin at 0, 5, 15, 45, 135, 405 and 1215 µg/mL, were prepared in 0.1 M phosphate buffer 
at pH 7.4. 10 ?L of these diluted solutions were added to 90 ?L of whole blood or plasma in 
order to obtain standard solutions with concentrations at 0, 0.5, 1.5, 4.5, 13.5, 40.5, 121.5 
µg/mL in tobramycin.  
 
2.3.2 Measurement micro-chambers in paper and paper-like materials:  
Grade 1 filter paper (Whatman, USA), cellulose diagnostic paper (C083 Cellulose Fiber 
Sample Pad Strips, Merck Millipore, Darmstadt, Germany) and unmodified glass microfiber 
sheets with PVA binder (G041 Glass Fiber Conjugate Pad Strips Merck Millipore, Darmstadt, 
Germany) were cut in 1 cm x 1 cm squares. Micro-chambers with a diameter of 7 mm were 
patterned with molten paraffin on the various paper and paper-like pads using a micropipette 
as a mask. Once in contact with the paper material, the paraffin directly solidified. The micro-
chambers were used only once for quantification. The volume of solution added for screening 
the different types of paper materials was 30 µL while for drug quantification in glass fiber 
micro-chambers, 10 µL was deposited. Once added into the detection micro-chamber, the 
liquids were driven by capillary action and occupied the whole chamber.  
Scanning electron micrographs were taken with a Field emission scanning electron 
microscope ZEISS LEO 1525 (Carl Zeiss, Oberkochen, Germany) with Everhart Thornley SE 
detector, Inlens SE detector and Oxford EDX Xmax 20 detector.  
 
2.3.3 Synthesis of the fluorescently-labelled tobramycin derivative: 
In order to test the FPIA in paper in the near-infrared range, an Atto655 tobramycin derivative 
(Atto655-Tob) was synthesized by formation of an amide bond between primary amine 11 of 
tobramycin and a succinimidyl ester of Atto 655 following protocols developed for the 
preparation of tobramycin haptens used to elicit antibody responses [103]. The derivatization 
is based on the differential basicity and nucleophilicity of the different amines of tobramycin 
with amine 11 being the most basic and reactive [104].  10 mg of tobramycin (21 µmol, 20 
equivalents) were dissolved in 50 µL milliQ water and 50 µL DMF, while 1 mg of Atto655 NHS 
ester (1.1 µmol, 1 equivalent) was dissolved in 500 µL dry DMF. The two solutions were mixed 
and stirred using a magnet for 1h on an ice bath at 5°C. 50 µL of the reaction mixture were 
2. Incorporation of Fluorescence Polarization Immunoassays into paper microstructures 
49 
 
then purified by Reverse Phase HPLC (1220 Infinity LC; RID detector 1260 Infinity and fraction 
collector 1260 ?AS, Agilent Technologies, California, USA) on a 5 µm Luna C18 column (25 
cm length, 4.6 mm internal diameter, 00G-4252-E0, Phenomenex, California, USA) at ambient 
temperature using a constant flow rate of 1 mL/min. The mobile phase consisted in a gradient 
acetonitrile / H2O (gradient 32% ACN - 49 % ACN in 10 min). A molecular mass of [M+H+] = 
977.46 (calculated: 977.5) was measured for ATTO 655-Tob (C45H68N8O14S) using an 
Accurate-Mass Q-TOF LC MS (6530, Agilent Technologies, Santa Clara, California, USA). 
Confirmation that Atto655-Tob was recognized by the antibodies was performed by measuring 
changes in fluorescence anisotropy in absence and presence of antibodies in 96-glass bottom 
well plates.   
 
2.3.4 Instrumentation for fluorescence-polarization measurements:  
A custom made optical setup was used for the measurement of the degree of polarization of 
the fluorescein derivative (Fluo-Tob) and Atto 655 derivatives (Atto655-Tob) of tobramycin in 
96-well titer plates and in paper and paper-like materials. 
The light from a diode laser at 470 nm (LDH-D-C-470, 20 mW PicoQuant, Germany) for Fluo-
Tob or from a He-Ne laser at 632.8 nm (PN 05-LHR-91, 1.5 mW,  Melles Griot, USA) for 
Atto655-Tob was directed either directly for diffraction-limited illumination or through a lens 
(500 mm focal length) for expanded illumination into the free entrance back port of an inverted 
optical fluorescence microscope (Olympus IX71, Olympus Corporation, Japan) equipped with 
a 10x/0.30 objective (PLNFLN, Olympus, Japan). Excitation intensities were adjusted using 
optical density filters so that fluorescence intensities were within the dynamic range of the 
detectors. The excitation light of the 470 nm diode laser was filtered using an excitation filter 
(MF 475-35, Thorlabs, Germany). Laser light was reflected into the objective using an 
appropriate dichroic mirror (for excitation at 470 nm: MD499, Thorlabs, Germany; for excitation 
at 632.8 nm: ZT633RDC, Chroma, USA). When using the lens, the area of illumination was 
around 90 µm in diameter as determined using a camera (Pco-edge sCMOS camera, PCO, 
Kelheim, Germany). Fluorescent solutions were either dispensed in paper and paper-like 
micro-chambers or in a 96-well microtiter plate with transparent glass bottom (Greiner Bio-One 
International, Austria). Alignment along the z-axis was performed manually based on 
transmission microscopy of the micro-chambers. 
Fluorescent light was collected by the same objective, passed through the dichroic mirror, the  
filter (MF525-39, Thorlabs, Germany) and was reflected out of the microscope through a lateral 
port into a polarizing beamsplitter (Thorlabs, Germany), which separated parallel and 
perpendicular polarization. Both beams were detected using low-noise photodiode detectors 
PDF 10 A, 200-1100 nm, Thorlabs, Germany). Acquisition time was 15 seconds. The samples 
were illuminated only during acquisition to minimize photobleaching. 
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The signal in mV of both diode detectors was read using a NI controlled by LabView (National 
Instruments, Austin, Texas). Background was subtracted from the signals and anisotropies 
were calculated using the following formula [90]:  
 
                                                                        ? ? ???????????????????????????                           (Equation 9 )                
 
 where r is the anisotropy, Ipar and Iper the intensities recorded for the parallel polarized and 
perpendicularly polarized beams and G ?????????????????-factor accounting for the difference 
??? ?????????? ??????????? ???? ???? ???? ??????? ???? ???-factor was determined by comparing 
measurements of anisotropies of 7 nM standard fluorescein solutions using the custom-made 
reader and a commercial SpectraMax Paradigm Multi-Mode Microplate Reader (Molecular 
Diagnostics, California, USA) operated with an excitation filer selected from 485 to 550 nm, an 
integration time of 150 ms and  a temperature of 25°C with 60 µL of the solution dispensed in 
a 384 flat bottom microtiter plate with non-binding surface (Corning Incorporated, USA).  
 
2.3.5 FPIA assays in serum and in whole blood 
 
One µL of whole blood or plasma previously spiked with tobramycin was mixed with 2 µL of 
Atto655-Tob in PBS at a concentration of 70 nM and 18 µL of tobramycin-antibody at the 
concentration provided by the supplier (Figure 2.3). After gentle manual mixing, reagents were 
left to incubate for 3 to 5 minutes at room temperature. 10 µL of this solution were then added 
onto the micr o-chamber, the focus was adjusted and the anisotropy was recorded at five 
different locations with the micro-chamber within a time span of typically two minutes.  
 
Figure 2.3: Scheme describing the competitive concept of FPIA using tobramycin antibody  
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The calibration curve was obtained by using serum or whole blood spiked with tobramycin at 
increasing concentrations encompassing the therapeutic range. The resulting calibration 
points were fitted in IgorPro 6 (WaveMetrics, Oregon) using a 4-parameter logistic equation: 
 
                                             ? ? ???? ? ???????????????????? ??????                                             (Equation 10)                
 
where r is the measured anisotropy, c the concentration, rmin the lowest anisotropy measured 
in presence of an excess of unlabelled tobramycin, rmax the highest anisotropy measured in 
absence of unlabelled tobramycin, IC50 the concentration value corresponding to the 
intermediate anisotropy and rate a parameter accounting for the slope of the calibration curve. 
Calibration curves were recorded on every measure 
ment day. Concentrations were back-calculated from anisotropies using the 4-parameter 
logistic equation. 
 
Statistics 
All error bars in figures and graphs are standard deviations obtained from measurements 
performed at least in triplicates (i.e. at least 3 independent solutions obtained by mixing and 
incubating the reagents and which were dispensed in different micro-chambers). Triplicates 
were measured at different times within the same day. 
 
2.4 Results and discussion 
 
2.4.1 Feasibility of fluorescence polarization measurements within paper and paper-like 
materials  
 
Three different types of paper and paper-like materials were investigated for their ability to 
accommodate accurate FP measurements: Whatman Grade 1 filter paper, cellulose diagnostic 
pads and glass microfiber sheets. These different materials were chosen as they strongly 
differed in terms of chemical properties, thickness, wettability, porosity and microscopic 
structure as displayed in scanning electron micrograph images (Figure 2.4 B, C, D). To simplify 
and standardize sample deposition, small 7 mm-wide circular micro-chambers for single-use 
measurements were created using a mask and wax impregnation (Figure 2.4 A). 
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red (? = 633 nm) and emission in the near-infrared region (? = 650-750 nm) (Figure 2.5). FP 
measurements in 96-well microtiter plates and in micro-chambers made of different paper and 
paper-like materials were performed using a custom-made reader developed around an optical 
microscope.  
 
 
Figure 2.5: Tracer used for tobramycin quantification. Chemical structure of Atto655-Tob. 
 
To assess the fluorescent background and the Raman scattering caused by the different 
paper-like materials, the signals recorded for a clear phosphate buffered saline solution (PBS)  
were compared with the signals obtained when using the same solution in a 96-well microtiter 
plate with glass bottom (Figure 2.6 A-B). Background signals were similar in microtiter plates 
and in glass fiber membranes, but higher in cellulose and in filter paper. This was observed 
both for an excitation in the blue at 470 nm (Figure 2.6 A) and for an excitation in the red at 
632.8 nm (Figure 2.6 B). The effect was much more pronounced in the green, which might 
indicate that the background was predominantly due to autofluorescence but also to the light- 
scattering effect that interferes more at shorter wavelengths, as shown previously [85]. The 
lower fiber density in the glass fiber membranes compared to cellulosic materials and the 
absence of some additives might explain why the effect was hardly noticeable in the former.  
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Figure 2.7: A. Anisotropy value measured for a 7nM solution of a fluorescein derivate of 
tobramycin in a 96-glass bottom well plate (reference measurement) compared to the 
anisotropy values measured for the same solution in micro-chambers made out glass fiber 
membranes, cellulose pads, and Grade 1 Whatman filters. B. Anisotropy value measured for 
a 7 nM solution of an Atto 655 derivate of tobramycin in a 96-glass bottom well plate (reference 
measurement) compared to the anisotropy values measured for the same solution in micro-
chambers made out glass fiber membranes, cellulose pads, and Grade 1 Whatman filters. 
 
Figure 2.8: A) Fluorescence intensity of the tracer Atto655-Tob at different concentrations, 
measured in paper; B) Anisotropy values measured for low concentrations of Atto-655 derivate 
compared to the anisotropy values measured in PBS in fiber-glass micro-chambers; 
Overall, glass fiber membranes with an excitation in the red exhibited the best properties for 
accurate determination of fluorescence polarization with very low background and 
anisotropies comparable to microtiter plate measurements and were therefore chosen for 
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In order to obtain a first rough estimate of the quantification range and the precision of this yet 
non-optimized assay, standard solutions were measured in triplicates on several days. Typical 
percentage coefficients of variation, %CVintra, assessed from back-calculated concentrations 
were determined to be below 20% within the therapeutic range (Figure 2.10 B). Analytical 
performance goals for TDM can be estimated by different ways [106]. For aminoglycosides, 
imprecision requirements expressed as %CV were recommended to be at least below 18% 
[107]. The FP immunoassay in glass fiber micro-chambers meets therefore preliminary 
analytical performance needs, even though if current clinical assays show %CV below 10% 
[24].  
2.4.4 Transversal separation of plasma and erythrocytes within glass fiber micro-
chambers 
 
One of the challenges in implementing new diagnostic assays for point-of-care testing is 
sample pre-treatment, in particular the separation step used to isolate plasma from whole 
blood, which is normally performed by centrifugation in a laboratory. Optical measurements 
are impaired in whole blood samples due to absorption and scattering by blood cells [108]. 
Blood separation techniques have already been exhaustively investigated on Whatman filter 
papers [109]. In our study however, the glass fiber micro-chambers are made out of glass fiber 
sheets with large pores used for conjugate release in lateral flow immunoassays. Yet we 
observed experimentally that separation occurred across the chamber with retention of blood 
cells on the upper side (at the site of deposition) while cleared plasma was apparent at the 
bottom of the micro-chamber (Figure 2.11 A).  
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 and it was found that a 15X or higher dilution of blood enabled accurate FP measurements 
with anisotropies identical to measurements in pure serum performed in 96-well microtiter 
plates (Figure 2.11 C). At a similar blood dilution, it was not possible to determine FP 
accurately in a well of a microtiter plate demonstrating that separation using the glass fiber 
membrane was critical to perform the FP measurements. 
 
2.4.5 Fluorescence-polarization immunoassays in glass fiber micro-chambers using 
whole blood  
 
The previous findings opened the possibility to perform a quantification of tobramycin from a 
drop of whole blood using straight forward steps as illustrated in Figure 2.12. 
 
 
 
Figure 2.12: Tobramycin quantification within glass fiber micro-chambers at the point-of-care: 
1 µL of whole blood, which might be obtained from a finger prick and collected using a glass 
capillary, was mixed with the tracer Atto655-Tob and antibodies against tobramycin. The 
solution was incubated for 3 minutes before addition of 10 µL to the glass fiber micro-chamber 
and anisotropy read-out at its bottom part. 
A drop of blood containing tobramycin, which could be typically collected using a fingerprick, 
was simply mixed with the reagents (antibody and tracer) and incubated for three minutes prior 
to addition to the glass fiber micro-chamber, where blood separation occurred at the upper 
part while drug quantification was performed at the bottom part. 
 
We investigated the feasibility of accurately quantifying Tobramycin using this procedure. 
Calibration curve could be recorded using standard solutions of whole blood spiked with known 
amounts of tobramycin (Figure 2.13 A). 
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Figure 2.13: Performance of a fluorescence-polarization immunoassay in glass fiber micro-
chambers for the quantification of tobramycin in whole blood;  
A. Representative calibration curve obtained using whole blood samples spiked with 
increasing concentrations of tobramycin and measured in triplicate within the same day. 
Tobramycin concentrations were chosen to encompass the therapeutic relevant range 
between 1 and 10 µg/mL. The red line is a fit of the calibration points using a four-parameter 
logistic equation yielding the following parameters: IC50 = 7.8 ± 1.6 µg/mL, rmin = 0.160 ± 0.004, 
rmax = 0.239 ± 0.006, rate = 0.6 ± 0.2. B. Concentrations of the standard solutions were back-
calculated from the anisotropy values using the four-parameter logistic equation and %CVintra 
were estimated. Mean %CVintra were obtained by averaging %CV recorded on 3 different days 
and were found to be typically around 20% within the therapeutic range. 
In order to obtain preliminary estimate of the quantification range, standard curves were 
obtained for several days and average %CVintra. were obtained by back-calculating 
concentrations. In general, a higher variability in terms of CV was observed with longer storage 
of the samples even if whole blood was used within the week (Figure 2.13 B). This might be 
due to haemoglobin release from red blood cells, that might interfere by absorbing light and 
by autofluorescence  even if the strong absorbing bands are predominantly in the range 
between 500-600 nm [110]. %CVintra. that would be obtained using fresh blood are therefore 
likely to be smaller. Currently, within the therapeutic range, %CVintra.  are between 20% and 
30% with a performance similar to the measurements in serum, which is quite remarkable. 
The limit-of-detection lies around 0.2 µg/mL, which is a clinical relevant concentration.  
 
To obtain first estimates for the performance in terms of precision and accuracy, control 
solutions were prepared by spiking tobramycin at low, medium and high concentrations 
compared to the therapeutic window and measured for several days. For the three controls, 
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imprecision is lower than 20% and recoveries are better than 20% range, within 100±20% 
range (Table 3), except for the high control  
 
Table 3: Analytical performance of the FP immunoassay in whole blood: Whole blood was 
spiked at low, medium and high concentration with respect to the therapeutic range of 
tobramycin. Average recovery and standard deviation of the recovery were assessed by 
performing measurements on three consecutive days. Recoveries remained within ±20%. 
 
 
 
 
 
 
 
 
 
The FPIA meets therefore the requirements for TDM of tobramycin even if a large potential for 
further improving performance exists. In particular, incorporation of the glass fiber micro-
chambers into a point-of-care device would significantly improve sources of imprecision 
caused by evaporation, temperature fluctuations and variations in incubation durations. 
 
2.5 Conclusions and perspectives 
 
With the advent of microfluidics in paper and paper-like materials for point-of-care applications, 
alternative detection formats are required. Here, we enlarged the arsenal of possible detection 
technologies by demonstrating that FPIA can be accurately performed within glass fiber micro-
chambers. The possibility offered by these micro-chambers to separate plasma from whole 
blood before quantification within the same chamber could prove to be an important asset in 
the development of solutions for point-of-care testing. Our study demonstrates that this novel 
combination of glass fiber chambers with FPIA makes realistic the development of a point-of-
care device for therapeutic drug monitoring using a single drop of blood. We speculate that 
the assay could be further simplified by incorporation and drying of the reagents within the 
micro-chambers and that the performance could be further improved by stabilizing 
temperature and environmental conditions inside a dedicated device. We envision that such a 
POCT device would allow for the transfer of therapeutic drug monitoring out of clinical 
laboratories directly to the physician????????? and even to the patients themselves
Range Nominal 
Concentration 
Mean %Recovery 
(±SD) 
  
 
Low 1.48     92 (17) 
Medium 3.51     105 (7) 
High 7.24       77 (14) 
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Chapter 3   
3. Fluorescence polarization immunoassays within micro-channels using 
compact optical readers 
 
Over the last decade, the miniaturization of analytical instrumentation has become an 
increasing trend among the biological and chemical sciences [111], bringing along advantages 
as small size, faster turn-around times and decreased costs [112]. The small sample size 
together with sensitive quantification assay, should prove useful for drug monitoring. However, 
when discussing about designing POC devices, integration of all components is fundamental. 
Microfluidic elements for sample collection, reagent mixing and blood separation as well as 
the detection chamber must be in such way interconnected that they do not interfere on the 
measurement result. This mutual compatibility can prove to be extremely challenging as more 
components are being integrated, because the technical requirements can vary greatly for 
each component or assay step [113].  
 
Although optical methods are the most used methods in analytical chemistry, there is a lack 
of miniaturized optical systems for small-molecule quantification[114], [115]. This might be 
attributed to the fact that optical devices require careful alignment, which might present 
challenges when translated into POC devices. In general, fluorescence remains the most 
widely used method of optical detection. Fluorescent detection has a number of advantages 
over other techniques, namely high sensitivity and a wealth of available fluorophores and 
labelling chemistries [116]. For fluorescence measurements, laser excitation is often used due 
to the fact that lasers have a low divergence and can easily be focused into a small illumination 
region. The ability to easily focus a laser beam into a small-spot delivers the advantages of 
high intensity and optical efficiency.   
 
As mentioned in previous chapters, in clinical settings, Tobramycin is mainly quantified via 
FPIA. FPIA instruments have been commercialized by Roche Diagnostics and Abbott 
Laboratories [107] [117], among others, and have been applied to TDM for various small 
molecules, including tobramycin. Due to its simplicity and speed, FPIA is amenable to 
miniaturization and automation [118]. Up to date, only one miniaturized FP system was 
described, however, using the standard well-plates for the measurements [119]. The 
possibility to use FPIA for quantification of the small drug theophylline directly within a 
microfluidic channel was recently demonstrated: Tachi et al, implemented this technique to 
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perform immunoassays within microchannels, but using a custom, non-compact optical setup 
[120].   
 
In this chapter, a miniaturized analytical device based on Fluorescence Polarization 
Immunoassays (FPIA) is described, which could be used for Therapeutic Drug Monitoring at 
the point of care. The compact optical device enables measurement of fluorescence 
polarization within glass microchannels, which are here mimicked with glass capillaries. The 
compact analytical system was applied to specifically quantify tobramycin from spiked plasma 
samples, directly within glass capillaries.  
 
To validate our demonstrator, different concentrations of Tobramycin were measured within a 
dynamic range covering the effective therapeutic window of the drug (2-12µg/ml). In this 
approach, the standard 384-well-plates measurements are replaced by the introduction of a 
new measurement chamber, glass capillaries, with a section of 1 mm2, which are prototypical 
of micro-fluidic channels made out of glass. Choice of glass capillaries was done considering 
mostly that, in the contrary to most polymers, light polarization is preserved while transmitted 
through the material. Polymers are not adapted for FP measurements directly as they are 
depolarizing light, but likely, paper-based micro-chambers might be used.  
 
For one measurement, 10 µl of mixed reagents were added into the glass capillary. The values 
obtained with our demonstrator agreed well with the commercial assay showing that 
tobramycin could successfully be quantified with a miniaturized optical device with reduced 
number of steps, volume of sample and reagents, allowing measurements in less than one 
minute for one analysis.  
 
3.1 Materials and methods 
 
3.1.1 Chemical Reagents  
All blood samples were bought from Interregional Transfusion Centre (Bern, Switzerland). 
They were collected from healthy volunteers in K3EDTA tubes, in order to prevent coagulation 
and they were shipped and stored at 4°C and used within a week from collection date. Plasma 
was obtained from whole blood centrifuged at 2000 rpm at 4°C for 20 minutes and it was kept 
at -20°C and used in less than a month. Fluorescently-labelled tobramycin and antibodies 
specific for tobramycin were from a commercial kit for FPIA on Roche Cobas Integra 400 
(Roche Diagnostics GmbH, Basel, Switzerland). Solutions of plasma samples were prepared 
by spiking Tobramycin at a concentration of 0-1210 µg/ml, followed by a dilution 10x in PBS. 
One µl of these solutions was incubated with 6 µL of Tobramycin derivative and 46 µL of 
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antibody for 5 minutes at RT. The calibration curves were prepared three times within a day 
and each sample was performed in triplicates. Furthermore, for inter-run reproducibility, the 
same tests were performed on 3 consecutive days.  
 
3.1.2 FPIA measurements 
The miniaturized optical device was validated by spiking human plasma. The concentrations 
used were: 0, 0.5, 1.5, 4.5, 13.5, 40.5, 121.5 µg/mL, covering the therapeutic range of the 
drug (1-12 µg/ml). 
All the measurements were performed at RT, in the dark, in order to reduce the background. 
The reagents were mixed previously in an eppendorf and added to the capillary with a pipette.  
A SpectraMax Paradigm Multi-Mode Microplate Reader (Molecular Diagnostics, California, 
USA) was used for reference fluorescence polarization measurements under the following 
conditions: excitation filer selected from 485 to 550 nm, integration time set at 150 ms while 
the temperature was set at 25°C. The fluorescence measurement readings in the UV region 
were performed in 384 flat bottom with non-binding surface microtiter plates (Corning 
Incorporated, USA), using a final volume of 80 µl per well.  
The capillaries were bought from C&M Scientific Ltd. (Livingston, UK). ID square 1* 0.20 mm 
thickness wall. Each capillary was manually placed horizontally in a previously manufactured 
(3D print) capillary holder attached above the microscope objective. Ten µl of human plasma 
was used for each measurement.  
 
3.1.3 Design of the miniaturized FP analytical device 
 
The miniaturized FP device, schematically represented in Figure 3.1, is divided in two parts: 
excitation of the sample and collection of the fluorescence signal.   
In order to have a stable polarized source, a non-polarized and pigtailed LED (Thorlabs - 
MF470) was used with a Glan Thompson Polarizer PGT (Thorlabs - GTH5M). The beam was 
collimated with the lens L1 (Thorlabs ? (A375 ?B (TL)). The LED emits on a wide spectrum 
(470 +/- 55 nm), thereby, an excitation filter Fs (Thorlabs ? MF475) selected a smaller band 
width (475 +/-15 nm). In order to focus the beam in the center of the capillary, a microscope 
objective L2 (Olympus - UPLFLN 10X2) was placed.  
The excited sample emitted fluorescence at another wavelength and unknown polarization. 
This beam was again collimated by the microscope objective L2. The dichroic mirror MD 
(Edmund Optics - 67-079) separated the emission and excitation beam. The dichroic mirror 
reflected the wavelength from 435 to 488 nm and transmitted from 520 to 730 nm. The 
fluorescence was furthermore filtered using an excitation filter (Thorlabs - MF530). 
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Figure 3.1: Scheme of the FP analyzer with a picture of the measurements within capillaries 
 
The polarizing beamsplitter cube PSB (Thorlabs ? PBS201) reflected S-Polarization and 
transmitted P-Polarization. The lens LV (Edmund Optics 20mm) and pinhole PV (Ø500um) 
made a confocal system between the capillary and the detector Dv (Thorlabs ? PDF10A/M) 
respectively LH, DH and PH. 
 
3.1.4 Detection unit including controlling software 
 
The signal was registered in mV and quantified by LabView software, which directly calculated 
the anisotropy (r), from the 2 measured intensities, parallel (??) and perpendicular (??), at the 
respective detectors. The G factor was calculated using, as reference, the anisotropy 
measured on a reference device (SpectraMax Paradigm Multi-Mode Microplate Reader), 
according to Equation 11. Anisotropy values were corrected using the G value. The G value 
was 0.92. 
                                                 ??????? ? ???????????????                                           (Equation 11),  
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where r is the anisotropy, ?? is the fluorescence emission measured in the plane parallel to the 
plane of excitation and ???is the fluorescence emission measured in the plane perpendicular 
to the plane of excitation.  
 
3.2 Results and discussion 
 
 
3.2.1 Compact FPIA analyzer using glass capillaries as detection chambers 
 
The benefits of assay miniaturization are now coming into focus because of the reported cost 
advantages of changing assay volumes from 100 µL down to 5 µL [121]. Although on chip 
measurements using FPIA have been previously studied [120], there has been however little 
effort as of yet towards the miniaturization of this technique.  
 
A compact, benchtop FP analyzer (Figure 3.2 A and B) was developed by Prof. Martial Geiser 
and his team and this setup makes use of an objective for the excitation and collection in order 
to focus the excitation beam within the microstructures. After an initial assembly of the setup, 
the functionality and optimization (i.e. alignment of the optical parts, sensitivity) of the analyzer 
were assessed by measuring different concentrations of fluorescein. Total fluorescence 
intensity as well as anisotropy were evaluated by comparison with a commercial device and 
the minimum concentration detected was 1 nM of fluorescein. The integrated intensities were 
comparable between the two devices, after correction with the G?factor and allowed us to 
proceed with drug concentration measurements.  
 
In terms of assay, the glass capillary could only accommodate very low amounts of sample 
and therefore, as a first step, the possibility to perform accurate FP measurements using low 
sample volumes was investigated. The assay was simplified and the volume of plasma was 
reduced to a minimum (1µL). The results obtained using the downsized assay were compared 
to measurements using standard sample preparation and volumes and performed in 386 well 
plates. Tobramycin could be quantified with the downsized FP assay with high precision 
(within-run CV < 10%) and accuracy (recoveries between 90 and 110%) in the therapeutic 
range of 1 to 12 µg/ml.  LOQ and LOD were 0.2 and 0.6 µg/ml, respectively. Under these 
conditions, the required sensitivity of the assay was achieved. Miniaturization was clearly an 
inherent capability of FP. The possibility that the FP assay for tobramycin could be performed 
?????????????????????µL opened the way to fully integrate it. For this, the assay was transferred 
from microplates to glass capillaries.  
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Figure 3.2: A) Compact optical device for FP quantification; B) picture of interior of the device 
with the different optical elements; C) Connection of the reader to the control PC; D) capillaries 
used as measurement chambers; 
 
Square glass capillaries were chosen as it was found experimentally that round capillaries 
deviated the illumination beam due to their shape. By contrast, when using tested squared 
capillaries, the shape of the illumination spot remained unmodified.   
 
For the following measurements, a volume of reagent mixture of 10 µL was used, which 
was10x fold less when compared with well plates. For one measurement, it typically required 
only 10 µL of plasma, previously diluted 10x with PBS, which demonstrated its aptitude for 
point-of-care therapeutic drug monitoring.  
 
3.2.2 Small-drug quantification in human plasma within glass capillaries  
 
The quantification of tobramycin concentrations in plasma samples by FPIA in capillaries was 
evaluated. Results showed that the performance obtained using the compact optical system 
were comparable with the results obtained using a commercial reader. Figure 3.3 plots the 
dose-response curves for Tobramycin quantification performed within glass-capillaries using 
plasma samples. 
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Figure 3.3: Dose-response curve for Tobramycin quantification within glass capillaries, 
obtained with the FP analyser; The black line is a fit of the calibration points using a four-
parameter logistic equation yielding the following parameters: IC50 =  7.704 µg/mL, rmin = 0.071 
± 0.004, rmax = 0.149 ± 0.006, rate = 0.89 ± 0.252. 
The analytical performance of the miniaturised FP optical system was evaluated in terms of 
reproducibility and sensitivity. The results show that the performance of the demonstrator is 
comparable with a commercial FP device in a range of concentration from 0-120 µg/ml 
Tobramycin.  
To determine the intra-run precision of the demonstrator, each of the standards containing 
tobramycin were tested 3 times within the day. In this case, the coefficient of variation (CVintra) 
varies within the triplicates from 15% to 30% within the therapeutic range of the drug. To 
measure each solution three times, each capillary was manually shifted to another position. It 
is not possible to know, whether it is measured on the same spot. The inter-run coefficient of 
variation (CVinter) was calculated using measurements performed in triplicates within the same 
capillary but at different locations, within the sample. However, the three different 
measurements spots within the same capillary were reproducible, with a coefficient of variation 
of 2%.  
The results of the measurements showed that, while the commercial FPIA device had a 
precision of 20%CV, the miniaturized analyser was slightly less precise, with a CV going up to 
30% (Figure 3.4)  
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Figure 3.4: Coefficient of variation comparison between the commercial device and the 
miniaturized FP analyser showing that the difference between the two is not considerable;  
 
Herein, if we compare coefficients of variation of the two systems results indicated that the 
analyzer was slightly less precise than the commercial one, the potential causes for 
imprecision can be attributed to the fact that the system is not automatized. The sample being 
placed manually handling errors might appear like for instance during the mixing step of 
sample with other reagents. Also, the system is not yet integrated with temperature and 
humidity control, key parameters for fluorescence polarization measurements. 
 
3.2.3 Integration with microfluidics: a whole-blood PDMS separator  
 
Microfluidic chips for immunoassays are commonly fabricated from silicon, glass, and polymer 
materials. The first generation of microfluidic devices were made from silicon and glass by 
photolithography and etching in a clean room based on well-established microfabrication 
techniques. However, polymers such as polymethylmethacrylate, cyclic olefin copolymer, 
polystyrene, and polydimethylsiloxane (PDMS) have emerged as alternative materials to 
silicon and glass due to the simple fabrication process (e.g., molding, embossing and printing) 
and low cost [122], [123]. Among the polymers, PDMS is the most popular material used for 
microfluidic immunoassays because of its flexible, optically transparent, biocompatible, and 
low-autofluorescence properties. Moreover, PDMS can be easily bonded to silicon, glass, or 
another piece of PDMS through treatment with oxygen plasma [114], [124] [125], [126]. 
 
Herein, we used a PDMS chip, designed by David Forchelet under the coordination of Prof. 
Philippe Renaud, from Microsystems Laboratory, EPFL. The microdevice is able to perform 
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blood separation at the point of collection. The capillary-driven microdevice processes 
fingerprick blood micro-samples without the need for external equipment. The device relies on 
sedimentation as a simple and spontaneous driving force for the separation of undiluted whole 
blood. The chip device has two main parts: the blood inlet and the plasma outlet. In addition 
to the separation channel, an ejection mechanism is present on the chip. A defined volume of 
2 ?L is ejected from the chip by using an air bubble and capillary valve. The ejection of the 
plasma allows for using the generated plasma in any on-chip or off-chip operation or 
characterization.  
 
The proof-of-concept, expressed in Figure 3.5, consists in the separation of whole blood, 
previously spiked with tobramycin, the collection of resulted plasma, mixed with the assay 
reagents and followed by FP measurements for the assessment of recovered drug. 
 
Initially, Tobramycin was spiked in whole blood and then added on the PDMS separation chip. 
After 15 minutes, when the separation was complete, 12.5 % of plasma was recovered. The 
flow through the microfluidic channel did not cause any visible haemolysis of RBC. 
Furthermore, the aim was to see if the concentration of tobramycin, previously spiked, could 
also be recovered.  
Plasma resulted from the separation was mixed manually with the reagents and then added 
to the measurement chamber. Mixing the assays reagents is another important step that can 
be further implemented onto the FP device.  
 
 
 
Figure 3.5: Proof-of-concept for separation and integration with the FP device: fresh whole 
blood was used for testing the PDMS microfluidic. 20 µL of spiked whole blood was added 
with the micropipette into the reservoir designed for sample collection. The separation was 
passive requiring 15?? ????????????????????????????????????????????????? of clean plasma was 
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obtained. Then, the plasma was mixed with the tracer and antibody and anisotropy was 
measured.  
Figure 3.6 shows a dose-response curve for Tobramycin. The assay was performed in 
triplicates and standard deviation was calculated.  
 
 
Figure 3.6:  Dose-response curve for the quantification of Tobramycin in whole blood using 
separation with the PDMS microfluidic device. The red line is a fit of the calibration points using 
a four-parameter logistic equation yielding the following parameters: IC50 = 1.854 ± 0.284 
µg/mL, rmin = 0.136 ± 0.0048, rmax = 0.238 ± 0.004, rate = 0.708 ± 0.191. 
The back calculated concentration of the tobramycin obtained after the whole blood separation 
was expressed in terms of recovery and had a value of 94.2 %, which is in the range of required 
recoveries for standard FP immunoassays (80 -120 %).  
 
3.3 Conclusions  
 
This study shows that is possible to develop a miniaturized and compact integrated optical 
system without using the standard well-plates for the fluorescence polarization measurements. 
As proof-of-concept, the analyser demonstrated its clinical adaptability when using human 
plasma samples. Moreover, measuring in glass capillaries holds the advantage of using small 
amounts of samples and reagents. The analytical performance obtained with the new system 
were comparable with those obtained on a conventional reader.
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Chapter 4   
4. Measuring challenging drugs: the immunossupressant case 
 
The following chapter will relate efforts in designing a FP immunoassay in order to determine 
the concentration of an immunosuppressant drug (ISD) within blood samples and, in particular, 
describe an improved drug extraction procedure. The aim of the following study was to develop 
a simple and fast method for tacrolimus quantification.  
Initially, chemical and biochemical properties of ISDs will be discussed highlighting the critical 
parameters that make their quantification challenging. Furthermore, we will overview the 
analytical methods used for their quantification, highlighting the needs for developing a rapid 
device for ISD qualification. To this reason, we will describe our efforts in designing an FP 
technique for Tacrolimus, one of the most used ISDs.  
 
4.1 Biochemistry of immunosupressants  
 
Immunosuppressant drugs such as sirolimus, everolimus, cyclosporine A and tacrolimus are 
effective for the treatment of organ or tissue rejection following transplant surgery [127] [128]. 
During the ISD therapy, monitoring the blood concentration levels is an important aspect of 
clinical care because insufficient drug levels lead to organ rejection while excessive levels lead 
to toxicities. Unfortunately, although all are very potent, some have a narrow therapeutic 
window and large inter-patient variability [129].  
 
They are categorized according to their mechanism of action as seen in Table 4:  
  
Table 4: Immunosupressive agents classified according to their mechanism of action 
[127][130]. 
 
Immunosuppressant Drug Classes Mechanism of action (target) Drugs 
Corticosteroids Regulation of gene expression  
(Glucocorticoid receptors) 
Prednisolone, methylprednisolone, 
and dexamethasone 
Antimetabolite/antiproliferative 
agents 
Inhibition of purine and pyrimine 
synthesis (inosine-??-monophosphate 
dehydrogenase) 
Azathioprine, cyclophosphamide, 
mycophenolate mofetil, and 
mycophenolate sodium 
Calcineurin inhibitors Kinase and phosphatase inhibitors  
(Calcineurin, JNK/p38 kinase) 
Cyclosporine, voclosporin*, and 
tacrolimus 
Mammalian target of rapamycin 
(mTOR) inhibitors 
Kinase and phosphatase inhibitors  
(Cyclin kinase cascade) 
Sirolimus and everolimus 
Costimulatory blocker Inhibition of CD28 mediated 
costimulation of T cells (CD 80 and 
CD 86 on antigen presenting cells) 
Belatacept 
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For nearly three decades, calcineurin inhibitors (CNIs) have been the most widely used form 
of immunosuppression in organ transplantation. CNIs have led to dramatic reductions in both 
acute rejection rates and early graft loss in renal transplantation. Long-term outcomes, 
however, are likely affected by CNI-associated allograft nephrotoxicity as well as 
cardiovascular risks such as diabetes, hypertension, and dyslipidaemia [131]. 
 
The lymphocyte blood cells host the immunosuppressive site of action for calcineurin inhibitors 
(CNIs), proliferation signal inhibitors (PSIs) and mycophenolic acid (MPA). Due to the fact that 
the intracellular compartment of lymphocytes is the target site of drug action, whole blood or 
plasma concentrations can only serve as substitute markers [132].  
Tacrolimus is a very lipophilic compound with a molecular weight of 804 Da, existing as a 
monohydrate in the solid state. It is highly soluble in methanol, chloroform, acetone and ethyl 
acetate, soluble in ethyl ether, propylene glycol and polyethylene glycol, but insoluble in water 
and n-hexane [4]. The rate of absorption of tacrolimus is variable with peak blood or plasma 
concentrations being reached in 0.5 to 6 hours; approximately 25% of the oral dose is 
bioavailable. Tacrolimus is completely metabolized prior to elimination. The mean disposition 
half-life is 12 hours and the elimination of tacrolimus is decreased in the presence of liver 
impairment and in the presence of several drugs. Tacrolimus has reported nephrotoxicity 
cases in 52% of the kidney transplants and 40% of the liver transplants [133], [134], [135], 
[136], [137]. 
 
4.2 Current analytical methods for TDM of immunosupressants and their limitations 
 
Various techniques are involved in the quantification of ISDs, all applied based on their 
chemical properties, bioavailability, target, metabolism, therapeutic range and protein binding. 
???? ????? ???????? ????????? ??? ???????? ???? ??? ????? ???? ????-automated or automated 
immunoassays (IAs) and liquid chromatography coupled with mass spectrometry (LC-MS) or 
tandem mass spectrometry (LC-MS/MS). Tacrolimus cannot be quantified by HPLC-UV 
because it lacks a significant chromophore [138]. Table 5 summarizes all the characteristics 
??????? ????????????????????????????????????.  
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4.3 Towards a POC device for ISDs   
 
Although LC-MS/MS method presents higher analytical specificity, lower reagent costs and 
multiplexing ability in measuring ISDs, they however require more complex sample pre-
treatment procedures, with longer turn-around times which may delay dose adjustment, 
especially during the early phase of organ transplantation procedure and thus, with higher 
risks of allograft rejection [169]. Immunoassays ?????????????????????????????????also require 
significant amount of sample and present high variability among the laboratories.  
     A POC device would enable the rapid turn-around time, especially in case of emergency or 
immediately after post-transplantation, when the dosage needs to be tightly controlled. 
Moreover, since the treatment with ISD lasts for a lifetime, a sample-to-answer device would 
simplify the life of patients by allowing less-invasive measurements. Moreover, the 
considerable amount of resources and expertise will not be required in case of a POC for 
?????? However, some of the factors that may influence the cost-effectiveness of a new 
??????????????????????????????????????????????????????????????????????????????????????? organ 
transplantation, cost of the treatment, cost of the test, and throughput [170].  
     For Tacrolimus, for instance, due to its distribution inside human red blood cells, the very 
low concentration and the narrow therapeutic window, an assay can become laborious in terms 
of sample preparation and implementation into microstructures.  
     Although various methods are applied for tacrolimus quantification, this chapter presents 
efforts in designing a novel FPIA for Tacrolimus.    
    Two fluorescent derivatives for tacrolimus were synthesized, which emit at different 
wavelengths. With both of these derivatives, a specific antibody (IgM) and the physiological 
protein target of tacrolimus, FK-BP12, were tested in affinity studies. One of the main results 
obtained using the fluorescence and anisotropy properties of the two tracers, is that the 
precipitation reagents used in extraction of tacrolimus highly influence the drug quantification 
efficiency.  
  
4.4 Experimental procedures 
  
4.4.1 Chemical reagents  
Tacrolimus (99 % purity), fluorescein-NHS (?ex 490 nm ? ?em 525 nm), ZnSO4 and the organic 
solvents were purchased from Sigma Aldrich (St-Louis, USA) while Atto 655 ? NHS ester (?ex  
648 nm ? ?em 668 nm) was purchased from ATTO-TEC (Siegen, Germany). IgM for Tacrolimus 
was purchased from Abcam and Biorbyt (Cambridge, United Kingdom) stored in Tris-buffered 
saline with as a preservative 0.1 % sodium azide.  
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4.4.2 Preparation and handling of whole-blood samples 
 
1 mg of tacrolimus was dissolved in 1mL of methanol and the solution was then diluted in TBS 
until a concentration of 20 µg/mL was achieved. Tacrolimus was further spiked in whole blood 
samples within a concentration range of 0-160 ng/mL. The extraction from blood samples was 
accomplished by mixing 400 µl of whole blood with 100 µl of ZnSO4 (300 mM) and 400 µl 
MeOH (50 %), respectively, into an Eppendorf. The Eppendorf tube was then rigorously 
vortexed for 15 seconds. 
The next step involved centrifugation for 10 minutes at 30k x G, at 4°C.The final stage 
consisted in decanting the clear supernatant in a new Eppendorf. This final solution was 
considered as the Whole Blood Extract (WBE).  
 
4.4.3 Synthesis of novel fluorescent derivatives for Tacrolimus:  
 
Synthesis of Fluorescein -Tacrolimus    
The derivatization procedure of tacrolimus has been performed by modification on C22 with 
amino-methyl-fluorescein. 29.4 mg (36.5 µmol) of tacrolimus was dissolved in 3.5 mL of 
anhydrous methanol and 16.7 mg (204 µmol) of sodium acetate and 40 mg (183 µmol) of O-
carboxymethyl hydroxylamine were added. The reaction was stirred at room temperature for 
12 hours under argon. Solvent was removed at reduced pressure to give crude solid residue.  
Furthermore, 6 mg of tacrolimus mono-oxime (6.85 µmol) were dissolved on 0.15 mL of 
anhydrous DMF. 2 mg of EDAC and 1.35 mg of N-Hydroxysuccinimide was added. The 
reaction was stirred at room temperature for 1h under argon. The product was further mixed 
with 5µL of trimethylamine and 0.5mL of 5-(aminomethyl) fluorescein in anhydrous DMF.  
The product was confirmed by the Accurate-MassQ Tof LC-MS, 6530 (Agilent Technologies, 
Santa Clara, California, USA) obtaining for Fluorescein-Tac (C67H85N3O18), (Figure 4.1 A), the 
nominal mass of M= 1219.58 g/mol, [M+H+] = 1220.58 g/mol. The purity obtained was 96%. 
For the analysis 0.91 mg of Fluorescein-Tacrolimus were dissolved in 1 mL of methanol and 
the stock solution was further diluted with TBS to the working concentration.    
 
Synthesis of ATTO655-Tacrolimus  
The synthesis in case of the red-emitting dye with tacrolimus was similar with the synthesis in 
of the green-emitting derivative, until the intermediate tacrolimus mono-oxime was formed.    
Furthermore, 1 mg of tacrolimus mono-oxime was dissolved in 0.05 mL anhydrous 
dymethylformamide. 0.33 mg of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) and 
0.22 mg of N-hydroxysuccinimide were added and the reaction was stirred at room 
temperature for 1h. The resulting compound was mixed with 0.25 mL of ATTO655 amine (1 
mg of ATTTO655 amine previously dissolved in 0.25 ml) and 1µL of triethylamine. The reaction 
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where [FP] is the equilibrium concentration of the tracer/protein complex and [P] and [F] are 
the equilibrium concentrations of free protein and free tracer.                                    
 
For the competitive assays, the resulting calibration points were fitted in IgorPro 6 
(WaveMetrics, Oregon) using a 4-parameter logistic equation, as described in section 2.3.5: 
 
                                                ? ? ???? ? ???????????????????? ??????  ,                                            (Equation 13) 
where r is the measured anisotropy, c the concentration, rmin the lowest anisotropy measured 
in presence of an excess of unlabelled tacrolimus, rmax the highest anisotropy measured in 
absence of unlabelled tacrolimus, IC50 the concentration value corresponding to the 
intermediate anisotropy and rate a parameter accounting for the slope of the calibration curve. 
 
4.5 Results and discussion 
 
4.5.1 Affinity and kinetic studies of Tacrolimus derivatives with bio-recognition 
molecules  
 
Fluorescence anisotropy is widely used for measuring high-affinity protein-protein interactions 
? among others and has been used for characterization of binding affinity studies for 
immunosuppressants [172]. However, an FP assay for tacrolimus quantification currently do 
not exist.  
 
Herein, for the design of FP assay for tacrolimus, two fluorescent derivatives were synthesized. 
Fluorescein-NHS was chosen for the derivatization of tacrolimus for excellent fluorescence 
quantum yield, and good water solubility. A red-emitting fluorophore, Atto655-tacrolimus, was 
also synthesized and would be preferred due to lower interferences with human samples, as 
showed in the case of tobramycin measurements in Chapter 2. 
 
The green and red-emitting derivatives of tacrolimus were explored in terms of binding affinities 
using a standard saturation experiment ????? ???? ??????? ????ific biorecognition molecules. 
Initially, FKBP12 protein (Figure 4.2 A) was chosen as is the tacrolimus natural binding protein 
[172], [173], [174]. The Atto655-tacrolimus was titrated w???????????????????????????????12 in 
buffer and 20% methanol. The organic solvent was used to simulate the extraction conditions 
and to understand the effect on the binding affinity. 
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Figure 4.3: Fluorescence anisotropy changes observed during titration of Fluorescein-
tacrolimus with IgM (Kapp = 50 nM), human serum albumin (HSA) and FKBP 12;  
While the titration of Fluorescein-tacrolimus did not lead to any response when FK-BP12, or 
HSA was added, the formation of complexes between Fluorescein-tacrolimus/IgM led to an 
increase of fluorescence emission anisotropy, having a Kapp of 50 nM. This result allowed to 
further design and optimize the assays with this antigen/antibody pair, although the affinity 
was low.   
     
Figure 4.4: Kinetic studies for the binding of IgM with the fluorescein derivative of tacrolimus; 
Different concentrations of tracer/IgM were tested and the pairs that showed a minimal binding 
(yellow, green, blue and grey markers) where then titrated with a fixed concentration of 
tacrolimus (10 nM) showing the displacement of the tracer from the antibody binding sites by 
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the drug (dark yellow, dark green, dark blue and dark grey); Standard deviations were 
calculated from triplicates; 
 
Kinetic studies of IgM with Fluorescein-tacrolimus were also performed (Figure 4.4) by testing 
and titrating different concentrations of the tracer and IgM antibody. After an equilibrium 
reached after approximatively 10 min, the addition of 10 nM of tacrolimus to the tracer/IgM 
complex led to a reduction of the observed anisotropy values.  
 
4.5.2 FPIA for tacrolimus quantification in clean target  
 
A new FP assay for tacrolimus quantification was designed in TBS buffer. Different 
concentrations of tacrolimus within the range of 0-100 ng/mL were spiked in TBS. The dose-
response curve illustrated in Figure 4.5 shows that the assay format might be suited for the 
concentration measurements of tacrolimus within therapeutic range, but with limited 
performance.  
 
Figure 4.5: Drug-response curve of tacrolimus quantification using Fluorescein-tacrolimus 
derivative, in TBS; each point was performed in triplicates.  
The assay showed a dynamic range at concentrations slightly higher compared with the 
therapeutic range but with good reproducibility among the replicates with standard variations 
between 0.001 ? 0.005.  
 
 
4.5.3 FPIA for tacrolimus in real samples  
 
Whole blood preparation represents a key step for tacrolimus quantification, as it will condition 
the correct quantification of the drug. In general, the immunosuppressants must be extracted 
and separated from the other components of the patient blood sample [175]. 
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In general, sample preparation procedure for tacrolimus implies several steps such as:  
 ?  Red-blood-cell lysis: usually performed with methanol;  ?  Protein precipitation: is performed with addition of ZnSO4 and/or an organic solvent   
such as methanol or acetonitrile;  ? Separation: which is usually performed by centrifugation;   
 
Extraction of FK 506 from its binding proteins from whole blood is usually achieved by addition 
of organic solvents [176] and methanol has been typically employed to extract tacrolimus and 
other ISD??[177]. However, a careful balance must be achieved such as the methanol is 
sufficient to liberate the drug from the binding protein but not so high as to interfere with the 
immunoassay. 
 
In our approach, different ratios of organic solvents for cell lysis and precipitation agents were 
evaluated with regard to the extraction efficiency and the matrix effects. Figure 4.6 B shows 
an image of the fresh whole blood samples after treatment with different sample preparation 
mixtures used for the protein precipitation and drug extraction. Initially, we tested the influence 
of methanol in 80% and 20% water only on the whole blood sample, which resulted in a highly 
heterogeneous solution indicating the lysis of RBC. After an optimization of sample preparation 
procedures, we transposed the assay to real whole blood samples. A concentration range 
(between 0-160 ng/mL) of tacrolimus spiked in whole blood was used (Figure 4.6 A).  
 
 
Figure 4.6: Dose-response curve of tacrolimus quantification using spiked whole blood 
samples; B) picture of whole blood extraction after different sample preparation strategies; The 
red line is a fit of the calibration points using a four-parameter logistic equation yielding the 
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following parameters: IC50 = 32 ± 3.3 ng/mL, rmin = 0.148 ± 0.007, rmax = 0.252 ± 0.016, rate = 
0.9 ± 0.3. 
When using spiked whole blood samples for tacrolimus quantification, by comparison with 
clean target, the dynamic range of the assay was shifted within a range of concentration of 10-
100 ng/mL. This might be explained by the fact that the binding affinities properties were 
changed using blood samples and the drug extraction procedures. However, although organic 
solvents are implied and which might affect the reproducibility of the assay, here the standard 
deviations (STD) among the triplicates measurements showed good reproducibility (0.001 ? 
0.006). Additional improvements should be performed in order to be able to quantify tacrolimus 
within the therapeutic range (10X fold reduction in concentration).  
 
 4.6 Conclusions  
 
Herein efforts in designing an FP method for tacrolimus have been described. FP could be an 
advantageous method for tacrolimus quantification due to its sensitivity but also mix and 
measure properties. For the assay design, two derivatives for tacrolimus at different 
wavelengths were synthetized and tested in terms of binding affinity with the biorecognition 
molecules. The green-emitting fluorophore/IgM was the pair that allowed the assay design in 
clean target for tacrolimus quantification within the therapeutic range. Our results suggest that, 
although FPIA is feasible for quantitative analysis for tacrolimus, the binding affinities but also 
extraction of the tacrolimus from RBC can be strongly influenced by the sample preparation 
procedures of whole blood. Having a significant impact on the quantification of the drug, 
sample preparation procedures could be further optimized by avoiding using organic solvents, 
for instance, for the lysis of the red blood cells in order liberate the tacrolimus/protein 
complexes but also to precipitate the proteins. 
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Chapter 5  
5. Conclusions and further perspectives 
 
This thesis presents various approaches to implement FPIA into microstructures with the aim 
to quantify small drug molecules in whole blood. While this assay format is well established in 
microtiter well plates or in cuvettes, the approach to perform FP measurements within 
microstructures remained unexplored to a large extent.  
 
As a first approach, paper and paper-based microstructures were chosen due to their low cost, 
biocompatibility but also ability to perform sample preparation. The goal was to test the 
feasibility of using paper and paper-based microstructures to host FP measurements. This 
study highlighted the importance to screen the different types of materials available like 
cellulose, filter paper and glass fibers and the various fluorophores in order to choose the best 
pair for anisotropy measurements. Glass fiber microstructures were selected for their low 
fluorescent background and scattering effect in combination with a red-emitting fluorophore. 
After optimization of the spot size and the number of measurements per detection chamber, 
the measurement errors significantly decreased. This enabled the accurate quantification of 
tobramycin within glass fiber microchambers in human plasma sample with CVs below 20% 
within the therapeutic range. 
 
The ability to measure FP in plasma in glass fiber microchambers was combined with the 
capacity of this membrane to separate whole blood. With prior optimization of whole-blood 
dilution, the anisotropy measurements in glass fiber sheets yielded values similar to the 
anisotropies obtained for plasma. Therefore, analysis were performed for the quantification of 
tobramycin previously spiked in whole blood. The results were very promising and indicated 
that, using fresh whole blood (i.e. within 24 h), tobramycin could be quantified with coefficients 
of variations between 20-30 % in the range 1-12 µg/mL, the therapeutic domain of the drug.  
 
The assay performance in paper still suffers from large coefficient of variations and this might 
be due to several different factors: temperature and humidity, which can affect the kinetic of 
the binding reaction, uncontrolled evaporation of the reagents once added to the paper and, 
possibly, also variations in the migration speed of the reagents.  In addition, errors in pipetting 
minute amounts of sample might have influenced the coefficients of variation.    
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Two major advantages were achieved by employing this approach of performing FP within 
glass fiber micro-chambers: the ability to use paper - based microstructures for the pre-
processing steps, using this way minute amounts of whole blood samples and, simultaneously, 
the ability to perform sensitive quantification of tobramycin within its therapeutic range. This 
last finding holds great promises for using the present technology as an alternative to clinical 
analyzers available in centralized institutions.  
 
Another motivation for selecting fluorescence polarization as a read-out was triggered by the 
possibility to perform quantitative assays on a compact detection system. In this approach, 
glass capillaries were used as detection chambers. Even if often reduction in size comes at 
the price of compromised performance, this was not the case for the novel optical device, 
which exhibited a preliminary performance similar to standards methods with coefficients of 
variation of 30% within the therapeutic range of tobramycin. 
 
Opportunities and challenges linked to the use of FPIA were revealed when implementing the 
assay for tacrolimus. On the one hand, a novel FP assay for tacrolimus could be developed 
that was able to quantify the drug in buffer within the therapeutic window 2-15 ng/mL. This was 
possible by synthesising and testing different fluorescent derivatives of tacrolimus emitting at 
different wavelengths. On the other hand, drug extraction from whole blood was found to be 
of critical importance and to adversely impact the performance of the assay so that further 
optimization procedures should be undertaken for the efficient extraction of tacrolimus.  
 
Possible further perspectives of this PhD thesis are described below:  
 ? Taking advantage of the results provided by the proof-of-concept study on the ability 
of FPIA to quantify molecules within paper, it would be very interesting to apply this 
methodology on samples from patients that are taking the drug.  
 ? Additional research would be desirable to make full use of the multi-functionality of 
paper and an improvement could be to further simplify the sample preparation 
procedure. An alternative for the simplification of sample preparation could be 
achieved, for instance, with the immobilization of the reagents through drying in the 
different microstructures (i.e glass fiber sheets or glass capillaries). However, in this 
format it might be difficult to control the incubation time after the resuspension of the 
antibodies or antigens, therefore this step should be kept in consideration as this might 
cause a lower sensitivity and may give false positive signals [178]. Another procedure 
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would be to re-design the paper platform so that the separation, mixing and dilution 
could be integrated, like is described by Osborn et. al.[179]. 
 ? It would be interesting to integrate the paper-based micro-chambers into a miniaturized 
analytical device: miniaturized medical devices require the combination of sample 
preparation platforms with sensitive read-out techniques. By carefully selecting the 
sample preparation procedures, the types of microstructures, multiple detection and 
quantification could be achieved within adequate concentration ranges.  
 ? The described FP system still requires further optimization in order to fully work as a 
POC test. A necessary improvement is to integrate the miniaturized analytical system 
with temperature and humidity sensors that would be able to measure and regulate 
these parameters.  Moreover, at present, the mixing of reagents and their addition to 
capillaries is performed manually. Since it was demonstrated that it possible to use a 
PDMS chip to separate whole blood, it could be considered in a new design to 
incorporate supplementary microchannels in order to perform also the mixing of 
reagents and the transfer into the detection capillary.  
 ? Simultaneous measurements of multiple drugs, i.e. multiplexing, would be a possible 
and desirable direction for future work.  
 
In conclusion, the capability of achieving sample-in answer-out within paper-based platforms 
would make a great contribution to the development of paper-based diagnostics for 
quantification of low-molecular weight therapeutics and it would represent a big step forward 
in improving patient care at the POC. Also, the design of a rapid and compact device like the 
one described herein, could open the path towards the development of a POC device for TDM.  
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